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Abstract
The demand for hip arthroplasty is increasing rapidly due to a combination of an
aging population as well as an increasing level of obesity in the country. The purpose of this
study is to evaluate the risks and benefits of arthroplasty for patients of different obesity
classes. The first two parts were to use a systematic review with meta-analysis and
retrospective chart review to quantify the risks and benefits in different obesity classes. The
third part was to perform a cost-effectiveness analysis to weight the balance between the two.
We found that higher obesity classes are at higher risk of complications and comparable
improvement after an arthroplasty. Our cost-effectiveness analysis determined that greater
obesity levels had a higher incremental cost-effectiveness ratio than lower obesity levels, but
was within generally used willingness-to-pay thresholds. In conclusion, patients of all obesity
levels have a greater benefit to cost ratio for total hip arthroplasty.
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Chapter 1

1

Introduction

1.1 Obesity
The World Health Organization (WHO) defines obesity as an abnormal or excessive fat
accumulation that presents a risk to health.1 The common metric used to measure obesity
is body mass index (BMI). It is calculated by dividing weight (kg) by the square of height
(m) resulting in units of kg/m2. The WHO categorizes individuals into different weight
classifications based on the magnitude of the BMI: underweight (BMI<18.5), normal
weight (BMI 18.50-24.99), overweight (BMI≥25.00), obese class I (BMI = 30.00-34.99),
obese class II (BMI = 35.00-39.99), and obese class III (BMI≥40.00).2 Due to major
clinical differences between the higher BMIs in obese patients, the medical literature
commonly further subcategorizes them as severe obesity (BMI > 35), morbid obesity
(BMI > 40), and super (morbid) obesity (BMI > 50).2–4 There are limitations to the use of
BMI to quantify obesity as it does not account for muscle versus fat mass, physical
characteristics, or racial differences. Another issue is that it does not account for the
distribution of fat since it can be central (abdominal) or peripheral (hip and thighs).
Central obesity is more strongly associated with diabetes, heart disease, and metabolic
syndrome.5 However, due to BMI's ease of calculation and widespread adoption, it has
become the standard for quantifying obesity.
The prevalence and severity of obesity has been increasing rapidly across the world. In
the early 1980s, obese individuals composed only 10.8% of Canada's and 14.7% of the
United States' adult population. By 2004-2006, those numbers doubled to 23.1% in
Canada and 33.9% in the United States6 (Figure 1-1). Similarly, European countries have
reported dramatic increases in obesity rates over the last few decades. France had a rate
of 6.3% in 1980, which increased to 16.9% in 2007, while the United Kingdom went
from 6.7% in 1982 to 22.7% in 2002.6 The increase in obesity rates is related to the rise
in conditions such as heart disease, stroke, high blood pressure, diabetes, sleep apnea, and
arthritis.6 These associated conditions drive increased medical resource use since their
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direct medical costs can be 36%-100% greater than the non-obese patient. It is estimated
in the United States that the annual healthcare costs due to obesity is $86-147 billion.
Obesity also leads to significant indirect costs, and it is estimated to cost $3.38-$6.38
billion from reduced productivity and absenteeism.7 The direct and indirect costs of
obesity in Canada are estimated to be between $4.6 and $7.1 billion.8

Figure 1-1: Trends in Overweight and Obesity Levels in the United States
Reprinted with permission from Derman, P. B., Fabricant, P. D. & David, G. The Role of
Overweight and Obesity in Relation to the More Rapid Growth of Total Knee
Arthroplasty Volume Compared with Total Hip Arthroplasty Volume. J. Bone Joint Surg.
Am. 96, 922–928 (2014).9

1.2 Obesity and Arthritis
Arthritis is a term for all processes that lead to swelling, stiffness, and pain in a joint. The
most common form is osteoarthritis, which is when cartilage, the smooth coating at the
end of bones, becomes worn out leading to the rubbing of bone on bone at the joint.10
Obesity predisposes patients to develop osteoarthritic changes in their hip and knee
joints. Obese individuals have been found to have a 60% greater likelihood of having
arthritis relative to the non-obese population.11 Evidence has demonstrated that increased
weight leads to increased biomechanical forces through the joints placing the individual
at a higher risk for wear and tear resulting in arthritis.12 Biomechanical studies suggest
that the hip experiences forces of three times body weight with single leg stance and the
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knee experiences forces four to five time bodyweight with activity.13 Another explanation
for the increased rate of arthritis development in obese individuals is their altered
metabolic state.15 Increased fat stores can release pro-inflammatory cytokines such as
TNFa and IL-6 which can cause cartilage destruction or alter cartilage metabolism even
in cases of osteoarthritis.14,16 Obesity also alters adipokine hormones including leptin and
adiponectin, which can have a pro-inflammatory effect. Through incompletely
understood pathways, it is thought these changes have deleterious effects on cartilage.17
Regardless of the exact etiology for developing arthritis, higher levels of obesity are
associated with an increased risk for undergoing a THA. A study by Bourne et al.
reported that obesity increased the relative risk for THA: 1.00 for non-obese, 1.92 for
overweight, 3.41 for obesity class I, 5.24 for obesity class II, and 8.56 for obesity class
III.18 Similar results were found in Australia, with a relative risk of 1.26 per every 5
kg/m2 increase in BMI (95% confidence interval (CI): 1.15-1.38).14
Higher BMI levels also increase the risk of undergoing an arthroplasty at a younger age.
Vulcano et al. found that each BMI obesity class was associated with having an
arthroplasty two years earlier than the next higher BMI class.19 Gandhi et al. found that
patients who had a BMI greater than 35 kg/m2 underwent a THA seven years earlier than
an individual with BMI less than 25 kg/m2.20 Another study reported an even earlier age
for undergoing arthroplasty, with morbidly-obese patients undergoing a THA 10 years
before those with a normal BMI.21
Concurrently with the growing obesity epidemic, there has been a rapid increase in
arthroplasties performed. Derman et al. reported that both THAs and TKAs have
increased dramatically from 1993 to 2009 (Figure 1-2).9 Derman evaluated factors that
affected the supply and demand of arthroplasty to identify the source of this growth, and
they determined obesity played a significant role in this increase.9
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Figure 1-2: Trend in THA and TKA Procedures in the United States from 19932009
Reprinted with permission from Derman, P. B., Fabricant, P. D. & David, G. The Role of
Overweight and Obesity in Relation to the More Rapid Growth of Total Knee
Arthroplasty Volume Compared with Total Hip Arthroplasty Volume. J. Bone Joint Surg.
Am. 96, 922–928 (2014).9
As a result of increasing rates of obesity, obese patients now comprise a greater
proportion of the arthroplasty population. Fehring et al. reported that 52.1% of their
arthroplasty patients were obese in 2005, and those numbers are higher now.22 Singh and
Lewallen reported that the severity of obesity is also increasing. Patients with a BMI
greater than 40 comprised 6.3% of the primary THAs performed in 2002-2005, which is
up from 2.3% in 1993-1995.23 In addition, arthroplasty rates are projected to increase
rapidly in the coming years. Kurtz et al. projected in the United States that relative to
2005, there will be a 174% increase in the number of THAs performed by 2030.24 The
rapid growth of obesity appears to be inextricably tied together with the rapid growth of
THA, and that raises the question of whether obese patients experience similar outcomes
following THA as non-obese patients.

1.3 Benefits of Arthroplasty for Obese Patients
There has been debate in the orthopedic community regarding how much obese patients
benefit from arthroplasty. Although evidence shows improvement in functional outcome
following arthroplasty25–28, there is controversy whether they achieve the same level of
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function as non-obese patients. McLawhorn et al. reported EQ-5D scores for normal,
overweight, obese class I, obese class II, and obese class III patients.25 The EQ-5D is a
standardized questionnaire to measure generalized health related quality of life. They
found that preoperatively, the obese class II (0.58±0.01) and III (0.54±0.03) patients had
lower utility scores than the normal weight patients (0.66±0.01). The lower scores
persisted two years after a THA with normal at 0.90±0.004, obese class II at 0.84±0.01,
and obese class III at 0.85±0.02, however the change scores were similar for all obesity
classifications. In fact, the obese class III cohort had a greater improvement following
THA compared to the normal weight cohort (0.31±0.02 vs 0.24±0.01, p = 0.0216).25
Other studies also suggest that despite having lower preoperative functional scores, obese
patients achieve the same degree of improvement after an arthroplasty.29,30 Although
obese patients clearly benefit from a THA, this comes with increased risks and
complications from surgery.

1.4 Risks of Arthroplasty for Obese Patients
The main concern for performing arthroplasty in obese patients is the risk for
perioperative complications. One contributing factor is that obese patients tend to have a
greater number of comorbidities. Odum et al. found nearly 30% of obese patients had
greater than 3 comorbidities compared to only 7% of the non-obese populations.31 The
comorbidities that are more common among obese patients include diabetes, metabolic
syndrome, and obstructive sleep apnea. Multiple studies have demonstrated that these
conditions are associated with a greater risk of perioperative complications that can lead
to an increased length of stay.32–36 Kremers et al. reported an increased length of stay of
0.16 days for every 5 kg/m2 over BMI 30.37
Infection is one of the most devastating complications following arthroplasty, and in an
obese patient the risk of infection is increased. Wagner et al. reported the hazard ratios
relative to the normal weight population for infection across a range of BMIs: obese class
I 1.6 (95% CI: 1.2-2.2), obese class II 1.9 (95% CI: 1.3-2.8), and obese class III 4.1 (95%
CI: 2.8-5.9).38 Similarly, they also found the risk for revision is higher relative to the
normal weight cohort: obese class I HR= 0.9 (95% CI: 0.8-1.01), obese class II HR=0.9
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(95% CI: 0.7-1.1), and obese class III is 1.3 (95% CI: 1.04-1.7).38 This study suggests
that patients with a BMI greater than 40 are at a dramatically greater risk of infection by
more than 4 times and revision by 30% compared to normal weight patients.38 Due to the
greater number of comorbidities among obese patients and increased risk of perioperative
complications, existing evidence suggests the overall cost of performing THA in this
population is also significantly greater.

1.5 Economic Considerations
Many studies have reported increased overall costs in higher BMI cohorts. For example,
Kim found that hospital costs for morbidly obese patients were 9% greater for primary
THA compared to non-obese patients.39 Dowsey et al. reported that the index
hospitalization costs AUS$128.91 (95% CI: $34.53-$223.28) more per unit of BMI
increase.40 Kremers et al. reported that every 5 units of BMI over 30 kg/m2 is associated
with a US$500 increase in hospital costs and US$900 greater 90-day costs after a primary
THA.37 The increasing demand for the procedure has led to changes in healthcare policy
placing a greater emphasis on decreasing costs for arthroplasty care. Some healthcare
systems are now instituting bundled payment plans for arthroplasty procedures where
physicians and hospitals will be held financially accountable for complications within 90
days of a surgery. The majority of these bundled payment initiatives do not risk stratify
patients.41 Given the known increased risks and costs of obese arthroplasty patients, many
providers have arbitrarily chosen specific BMI cut-off levels (anywhere from 35-45) to
determine eligibility for an arthroplasty procedure. These cut-off levels were determined
only considering the short-term risk of complications and increased costs without any
evaluation of the long-term benefit of arthroplasty in obese patients. There have been no
cost-effectiveness analysis published for obese arthroplasty patients to guide this decision
to justify a cut-off threshold. A more thorough evaluation of both the risks and benefits
over the long-term is warranted prior to instituting BMI cut-off levels.
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1.6 Rationale for Study
With increasing obesity levels and resulting rising demand for arthroplasty procedures, it
is crucial to evaluate the most efficient allocation of resources to achieve optimal patient
outcomes. Due to greater comorbidities and increased risk of complications, performing
arthroplasty for obese patients is more expensive. However, given that obese patients also
experience significant benefit from the procedure, there is a need to evaluate the value of
THA in this population. With increasing population weight, more people are in higher
BMI groups (BMI>45 and 50) that weren’t developed when the WHO BMI categories
were initially defined. Subjective surgical experience and reporting in the literature
suggests that the higher BMI categories carry with them a higher complication rate and
subsequent cost. There is a need to evaluate the cohorts at the extreme end (BMI above
45 or 50) and understand how to appropriately establish risk and stratify costs. The
objective of this research is to evaluate the magnitude of the benefits and risks associated
with primary THA for patients with varying BMI levels (including patients with a BMI
above 45 or 50) and to estimate both short term (90-day) and long term economic
implications.

1.7 Economic Analysis Tools
One of the tools to conduct health economic analysis is the Markov model, which is a
diagram representing all the possible health states an individual can have and the possible
paths to change health states.42 Each of the health states and transitions between them
have a cost and/or utility score (a metric to quantify the health of an individual with 1
representing perfect health and 0 death) tied to it. There is a probability associated with
each of the transitions and the model is cycled a predetermined number of times to
simulate the individual passing through different health states over the time period of
interest. By tallying the costs and utility scores over the time period of interest, the total
costs and utilities can be quantified. If a time period of one year is utilized, the utilities
can be simply summed to have units of quality-adjusted life years (QALYs). One QALY
means having a utility score of 1 (perfect health) for one year. Consequently having a
utility score of 0.5 for 2 years of a utility score of 1 for 1 year would be equivalent
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QALYs.43 For time periods other than one year, the utility score will need to be adjusted
for the year to calculate a QALY.
In cost-effectiveness analysis, generally two different treatment options are
compared using the average cost-effectiveness ratio (ACER) or the incremental costeffectiveness ratio (ICER). The ACER is calculated by dividing the total cost of a
treatment by the total QALYs it provides. Then the ACER value for the two treatment
options are directly compared. Historically, this was the more common metric to compare
the cost-effectiveness of treatment options. However, this approach is limited in
situations where one treatment option provides a significant number of QALYs for a low
cost and the other treatment provides slightly more QALYs for a much greater cost. The
ACER value for both treatment options could be within reasonable levels, but in the
second treatment the sizeable additional cost to get a small improvement in QALYs may
not be justified. As a result, ICERs are the standard metric used in cost-effectiveness
analysis currently. It is calculated by determining the incremental cost and QALY gains
with one treatment over another and then taking the ratio. By this method, treatments that
provide small additional QALY gains at a much higher cost can be easily identified.44
The ICER number can be compared against different willingness-to-pay (WTP)
thresholds to determine if the treatment is cost-effective. This WTP number is based on
what society would determine as an appropriate cost for obtaining one additional QALY.
There is controversy over whether or not to use this assessment. In cases where it is used,
there is debate over how the WTP level should be determined. Commonly the WTP is
determined based on standards set by other accepted medical interventions, such as an
ICER of US$50,000-100,000+ for a lifetime of dialysis. As a result some studies use a
WTP of US$50,000-100,000.45 We will apply these tools to determine the costeffectiveness of THA for different BMI levels.

1.8 Study Objectives
1) To systematically review the existing literature and determine differences in
reoperations, aseptic and septic revisions, and change in functional outcome
scores for various BMI categories.
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2) To assess 90 day costs and mid-term outcome scores for the following BMI
categories: <25, 25-29.9, 30-34.9, 35-39.9, 40-44.9, and 45+.
3) To estimate the cost-effectiveness of THA compared to nonoperative
management among these BMI categories over 15 years.
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Chapter 2

2

A Systematic Review and Meta-Analysis of Revision
Rates and Functional Outcome Scores for Severely,
Morbidly, and Super-Obese Primary Total Hip
Arthroplasty Patients

2.1 Introduction
The demand for hip and knee arthroplasty is rising rapidly due to a combination of an
aging population as well as an increasing level of obesity in the US and Canada.1–4 Obese
patients (BMI>30) who undergo an arthroplasty report significant improvements in pain,
function, and activity levels after the procedure.5 However, obese patients are at a greater
risk for perioperative complications, infections, revision,6–8 and increased costs of care.9
All patients with a BMI greater than 30 are not same. The degree of obesity impacts the
level of risk and benefits for the individual. Since both the extent and degree of obesity is
rising worldwide, studies have begun investigating the impact of having a BMI greater
than 35, 40, 45, and even 50 on outcomes following arthroplasty.8,10–14 Current
studies10,12–14 tend to have small sample sizes followed for a few years post surgery, or
larger patient populations analyzed for short follow up times of a few months.8 Prior
systematic reviews and meta-analyses15–17 focusing on outcomes of total hip arthroplasty
with obesity have only evaluated outcomes in patients with a BMI greater than 30. These
studies may be missing important differences in outcomes with higher BMIs. For
example, Wagner et al.18 found that revision rates are only significantly greater than the
non-obese cohort at a BMI greater than 40. We therefore propose a systematic review and
meta-analysis assessing the outcomes for patients following THA separated into BMI
categories greater than 30.
The purpose of this study is to perform a systematic review and meta-analysis to
determine differences in functional scores, reoperations, and aseptic and septic revisions
following THA in severely (BMI>35), morbidly (BMI>40), and super-obese (BMI>50)
patients versus a non-obese BMI population (BMI<25). We hypothesized that there
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would be an increased risk for reoperations, aseptic, and septic revisions for the higher
BMI categories, while the functional scores would be comparable.

2.2 Methods
We conducted a systematic search of the online bibliographic databases Medline (1946 to
week 3 of August 2016), AMED (1985 to August 2016), Ovid Healthstar (1966 to
August 2016), and Embase (1947 to week 3 of August 2016) to identify studies
evaluating outcomes between varying BMI categories. We used database appropriate
search terms including a combination of synonyms for obesity (obesity, body-mass index,
overweight) linked with hip arthroplasty or replacement found in the abstract, title, text
words, or keywords. The search was limited to articles written in the English language.
The reference lists of included studies were reviewed to identify any additional studies
that would be eligible. Three pairs of reviewers assessed the titles and abstracts of articles
found in the initial search for eligibility. Eligible studies included those that 1) evaluated
primary total hip arthroplasty outcomes by BMI, 2) BMI was evaluated as a categorical
variable and the highest BMI category was at minimum 35 or above, and 3) included the
outcomes of interest (reoperations, revision (aseptic and septic) and change scores
(preoperative to postoperative) of functional scores). All titles and abstracts that met the
eligibility criteria and any marked uncertain were obtained in full text for further review.
Each abstract and full-text article were independently reviewed by two authors using the
same eligibility criteria. Any discrepancies were discussed between the authors until a
consensus was reached. In cases of duplicate reports on the same patient sample, we
chose to include the most recent study. We calculated a Kappa statistic to provide a
measure of interobserver agreement for study eligibility. The Kappa statistic is a standard
tool used to measure the degree of interobserver agreement beyond chance alone.19
A quality assessment of the included studies was performed with the ROBINS-I tool for
non-randomized studies developed by the Cochrane Bias Methods Group.20 This tool
assesses internal validity based on seven criteria including 1) bias due to confounding, 2)
bias in selection of participants into the study, 3) bias in classification of interventions, 4)
bias due to deviations from intended interventions, 5) bias due to missing data, 6) bias in
measurement of outcomes, and 7) bias in selection of the reported result. For bias due to
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confounding we assigned a low risk of bias to studies with a prospective design and
retrospective studies with matched cohorts or analysis controlling for baseline factors,
while a moderate risk of bias was attributed for other retrospective studies. For selection
bias, studies were considered at serious risk of bias if they excluded those that did not
meet a minimum follow-up requirement (ex. retrospective study requiring 1 year followup therefore missing patients with early complications). For bias in classifications of
interventions, we considered how BMI was measured. If BMI was directly measured it
was defined as low, if obtained retrospectively from a patient chart defined as moderate,
or if patient self reported defined as serious. For deviations from intended intervention,
we assessed the risk of bias based on whether there was differential treatment between
the BMI cohorts. For bias due to missing data, if studies had less than 15% missing data
and similar distributions across BMI categories it was graded as a moderate risk of bias.20
If the proportion of missing data was greater than 15% or there was differential missing
data it was considered a serious risk of bias. For bias in outcome measurement, we
considered items such as subjective or objective outcome, blinding and differential
outcome assessment between BMI categories. Bias in reported results was based on
whether all planned analyses proposed in the methods were included in the results.
Information about specific databases/registries gained from other literature sources were
utilized to evaluate the risk of bias in other papers using the same data source if data was
missing or not clear in the original report.
For the meta-analysis, results were categorized into severely (BMI>35), morbidly
(BMI>40), and super-obese (BMI>50) patients, and were compared to a non-obese
(BMI<25) group within the same paper. If the paper did not have a BMI less than 25
group, then the smallest equivalent BMI group was used for comparison. Data was
extracted from all eligible studies. In addition to recording author name, study title,
journal name, issue, and page numbers; we extracted number of patients, patient
demographics, means, standard deviations, range, 95% confidence intervals, interquartile
range and change scores for functional outcomes and event rates for reoperations and
aseptic and septic revisions. If the change in functional outcome scores was not provided,
they were calculated based on the difference in means from preoperative to postoperative.
In these cases, the standard deviation of change scores were estimated to be the same as
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for comparable studies with the same functional outcome scores that provided change
scores with standard deviation. The order of preference for functional outcome scores
were: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC),
Oxford Hip Score, Harris Hip Score, and EuroQol (EQ-5D). Authors were contacted
when data in the paper was unclear or missing. Meta-analysis was performed using a
random effects model where appropriate. Change scores were converted to standardized
mean difference for comparison across studies using different outcome measures.
Relative risks were used as summary measures for reoperation and revision rates. We
calculated pooled estimates and 95% confidence intervals (CI) for both the standardized
mean difference and relative risk.
We performed heterogeneity calculations using the I2 statistic on all outcomes. Sensitivity
analyses for short (less than a year) and longer (equal to or greater than a year) follow-up
were performed for all outcomes. All calculations were performed with RevMan software
(RevMan 5.3, Cochrane Collaboration, London, United Kingdom).

2.3 Results
We identified 1,692 potentially relevant articles from the literature search. We screened
448 full-text articles and 33 studies met the eligibility criteria and were included in the
final analyses (Figure 2-1). Inter-rater agreement was good-to-excellent for determining
eligibility for titles and abstracts (Κ=0.84) and full-text articles (Κ=0.84).
Our quality assessment identified 2 prospective studies, 6 retrospective studies with
matched comparison group, and 2 retrospective studies with controlled analysis (Table 21). The remaining 23 studies were retrospective studies without a matched comparison
group or controlled analysis. Bias due to selection and missing data were the most
frequent. Lack of information provided in reports made bias in classification of BMI and
deviation from intended intervention difficult to evaluate. Overall, for the majority of
studies and categories, the studies had moderate to serious risk of bias (Table 2-2).
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Figure 2-1: Flowchart of Article Selection
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Table 2-1: Demographics of Included Studies
Demographics of Included Studies. R = Retrospective, P = Prospective, M = Matched cohort, C = Controlled analysis, N/A =
information not available in paper
Non-Obese Cohort
Study

Obese Cohort(s)

Study
Type
R

BMI
18.5-25

N
865

Age
66.35±0.36

Sex
(%Female)
70.8

R, C

18.5-29.9

10997

N/A

58.6

R
R
R
R
R, M

<35
18.5-25
18.5-40
<30

1417
186
45895
985

<30
<30
<50
20-24.99

135
274
84
1136

63.3±11.0
67.2±13.9
65.4±12.0
N/A
55 (range:
48-75)
N/A
56.7±11.6
69.18±12.03

19-29.9

1640

19-29.9
<30
18.5-25

1738
21574
864

56.7
54.3
55.2
N/A

BMI
35-40
>=40
35-39.9
>=40
>=35
>=40
>40
>35

n
186
73
2557
1596
204
39
3580
144

N/A
N/A
70.0
63.1

>=50
>40
>=50
>40

74.3±7.6

62.5

66.7±9.6
N/A
N/A

56.3
N/A
N/A

McLawhorn et. al. (2016)
Fu et. al. (2016)
Purcell et. al. (2016)
Hanly et. al. (2016)
Walls et. al. (2015)
Lash et. al. (2013)
Issa et. al. (2016)
Foster et. al. (2015)
Arsoy et. al. (2014)
Murgatroyd et. al. (2014)
Jameson et. al. (2014)
Cemented Stems
Jameson et. al. (2014)
Cementless Stems
Khatod et. al. (2014)
Judge et. al. (2014)

R
R, M
R
R

Sex (%Female)
51.6
52.1
53.7
59.6
60.3
76.9
60.8
N/A

45
23
42
219

Age
61.90±0.65
60.51±1.08
N/A
N/A
59.3±10.26
61.4±9.6
60.5±9.8
N/A
54 (range
36-71)
N/A
56.5±12.3
59.95±10.02

>=35

321

70.7±7.4

72.3

>=35
>=35
35-40
>40

428
5778
150
47

62.9±9.1
N/A
N/A
N/A

58.2
N/A
N/A
N/A

N/A
72.0
62.6

R
R
R
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Table 2-1 (continued): Demographics of Included Studies
Demographics of Included Studies. R = Retrospective, P = Prospective, M = Matched cohort, C = Controlled analysis, N/A =
information not available in paper
R, M
Issa et. al. (2013)

<25

46

18.5-24.9
18.5-30
<25

39
17569
1105

<25
<30

52
113

20-30
18.5-24.9

142
6102

<25

647

<30
<30
<30

55
277
623

20-25
<30
<25

29
1069
301

R, M
Rajgopal et. al. (2013)
Namba et. al. (2012)
Jamsen et. al. (2012)
Jones et. al. (2012)
Michalka et. al. (2012)
Lehman et. al. (1994)
Traina et. al. (2011)

R
R
R
R
R
R
R

McCalden et. al. (2011)

N/A
53.1 (range
29-72)
N/A
N/A
N/A
67.7±13.20
48 (range
19-73)
N/A
71.0 (range
23.7795.74)

N/A

>=50

23

85.0
N/A
N/A
N/A
58.4

>50
>=35
35-39
>=40
>=35
>=35

39
4754
559
193
32
21

25.4
71.0

>=40
>=40

8
187

70.6

206

77.4
58.1
N/A

>=40
>=40 or
>=35 with
1 major
comorbidity
>=40
>=40

72.4
62.4
N/A

>=40
>40
>=40

29
18
44

R, M
Chee et. al. (2010)
Dowsey et. al. (2010)
Judge et. al. (2010)
Bennett et. al. (2010)
Andrew et. al. (2008)
Dowsey et. al. (2008)

P
R
R, M
P
R

63.6 (range
45-83)
68.6±10.8
N/A
61.6 (range
43-74)
69.1±11.1
N/A

55
21
11

50 (range
25-71)
53 (range
31-72)
N/A
N/A
N/A
65.4±8.96
52 (range
37-72)
N/A
59.7 (range
26.5182.36)
63.7 (range
45-83)
65.6±10.7
N/A
61.4 (range
42-74)
60.6±12.3
N/A

55.0
83.0
N/A
N/A
N/A
42.9
25.0
66.8
63.6

77.4
85.7
N/A
72.4
72.2
N/A
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Table 2-1 (continued): Demographics of Included Studies
Demographics of Included Studies. R = Retrospective, P = Prospective, M = Matched cohort, C = Controlled analysis, N/A =
information not available in paper
McLaughlin et. al. (2006)
Namba et. al. (2005)
Jibodh et. al. (2004)

R
R
R
R

20-25
<=35
<25
<25

33
922
51
131

N/A
66±13
68±12
N/A

N/A
57.0
63.0
N/A

R, C

<30

702360

N/A

61.0

Stickles et. al. (2001)
Werner et. al. (2016)

>=35
>35
>=40
35-40
>40
40-49.9
>=50

30
149
18
51
27
62556
3244

N/A
62±9
59±15
N/A
N/A
N/A
n

N/A
62.0
78.0
N/A
N/A
66.3
72.2
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Table 2-2: Summary of Quality Assessment of Included Studies. 1 = Low risk of bias; 2 = Moderate risk of bias; 3 = Serious risk
of bias; NI = Not enough information to evaluate.

Confounding
McLawhorn et. al.
(2016)
Fu et. al. (2016)
Purcell et. al. (2016)
Hanly et. al. (2016)
Walls et. al. (2015)
Lash et. al. (2013)
Issa et. al. (2016)
Foster et. al. (2015)
Arsoy et. al. (2014)
Murgatroyd et. al.
(2014)
Jameson et. al. (2014)
Khatod et. al. (2014)
Judge et. al. (2014)
Issa et. al. (2013)
Rajgopal et. al. (2013)
Namba et. al. (2012)
Jamsen et. al. (2012)
Jones et. al. (2012)

Selection
of
Participants Classification
in Study
of BMI

Deviation
from Intended
Intervention

Missing
Data

2
1
2
2
2
2
1
2
1

3
2
2
3
2
2
2
3
2

3
1
NI
2
1
NI
2
2
1

NI
NI
2
NI
NI
NI
2
NI
NI

3
2
NI
NI
2
3
NI
2
3

2
2
2
2
1
1
2
2
2

2
3
2
2
2
2
2
3
2

NI
3
2
NI
NI
2
2
2
2

NI
NI
NI
NI
2
2
3
2
2

2
2
2
3
NI
NI
NI
NI
2

Measurement
of
Reoperation/
Aseptic/Septic
Revisions

Measurement
of Functional
Outcome
Scores

Selection
of
Reported
Result

2

2
2
2
2
2
2
2
2
2

1
2
2
1
2
2
2
2
2
2
2
2
1

2
2
2
2
2
2
2
2
2

2
2
2
2
2
2
2
2
2
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Table 2-2 (continued): Summary of Quality Assessment of Included Studies. 1 = Low risk of bias; 2 = Moderate risk of bias; 3 =
Serious risk of bias; NI = Not enough information to evaluate.
Michalka et. al. (2012)
Lehman et. al. (1994)
Traina et. al. (2011)
McCalden et. al.
(2011)
Chee et. al. (2010)
Dowsey et. al. (2010)
Judge et. al. (2010)
Bennett et. al. (2010)
Andrew et. al. (2008)
Dowsey et. al. (2008)
McLaughlin et. al.
(2006)
Namba et. al. (2005)
Jibodh et. al. (2004)
Stickles et. al. (2001)
Werner et. al. (2016)

2
2
2

2
3
2

1
2
NI

NI
NI
NI

2
2
NI

2
1
1
2
1
1
2

3
3
2
2
3
2
2

2
3
1
NI
NI
NI
NI

2
2
NI
NI
2
2
NI

2
2
2
3
NI
3
2

2
1

2
2
2
2
1

2
2
2
3
2

NI
2
NI
NI
3

2
NI
2
NI
NI

2
2
NI
3
NI

2
1
2

2

2
2
2

2

2
2
2
2
2
2
2

NI
NI

2
2
2

2
2
2
2

2
3

2
2
2
2
2
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BMI>3521–25
Study or Subgroup
Fu et. al. 2016
Jameson et. al. 2014-1
Khatod et. al. 2014
McLaughlin et. al. 2006
Purcell et. al. 2016

BMI>35
BMI<25
Risk Ratio
Events Total Events Total Weight M-H, Random, 95% CI
174
24
110
15
7

Total (95% CI)

6427
749
5778
30
204
13188

210 13099
61 3378
371 21574
23
33
13 1417

25.4%
19.0%
25.2%
20.1%
10.3%

1.69 [1.38, 2.06]
1.77 [1.11, 2.83]
1.11 [0.90, 1.37]
0.72 [0.47, 1.09]
3.74 [1.51, 9.26]

39501 100.0%

1.40 [0.97, 2.02]

Total events
330
678
Heterogeneity: Tau² = 0.13; Chi² = 23.17, df = 4 (P = 0.0001); I² = 83%
Test for overall effect: Z = 1.80 (P = 0.07)

Risk Ratio
M-H, Random, 95% CI

0.01

0.1
1
10
Favours BMI>35 Favours BMI<25

100

BMI>408,21,26–31
Study or Subgroup
Andrew et. al. 2007
Chee et. al. 2010
Fu et. al. 2016
Lehman et. al. 1994
McCalden et. al. 2011
Murgatroyd et. al. 2014
Traina et. al. 2011
Werner et. al. 2016

BMI>40
BMI 18.5-25
Risk Ratio
Events Total Events Total Weight M-H, Random, 95% CI
0
5
183
0
11
5
4
289

18
55
5386
8
206
219
187
4246
10325

Total (95% CI)

0.1%
0.1%
29.2%
0.1%
2.2%
1.1%
1.2%
65.9%

1.94 [0.12, 31.38]
11.00 [0.62, 194.25]
2.12 [1.74, 2.58]
0.59 [0.04, 9.12]
1.73 [0.84, 3.54]
1.53 [0.57, 4.09]
0.97 [0.36, 2.59]
2.00 [1.76, 2.28]

46281 100.0%

2.01 [1.81, 2.23]

14 1069
55
0
210 13099
13 142
20 647
17 1136
135 6102
817 24031

1226
497
Total events
Heterogeneity: Tau² = 0.00; Chi² = 5.00, df = 7 (P = 0.66); I² = 0%
Test for overall effect: Z = 12.92 (P < 0.00001)

Risk Ratio
M-H, Random, 95% CI

0.01

0.1
1
10
Favours BMI>40 Favours BMI<25

100

BMI>508,10,12–14
Study or Subgroup
Arsoy et. al. 2014
Issa et. al. 2013
Issa et. al. 2016
Rajgopal et. al. 2013
Werner et. al. 2016
Total (95% CI)

BMI>50
BMI<30
Risk Ratio
Events Total Events Total Weight M-H, Random, 95% CI
5
4
5
6
25

42
23
45
39
284

7
84 15.0%
1
46 0.0%
3 135 9.5%
0
39 2.4%
817 24031 73.2%

1.43 [0.48, 4.23]
8.00 [0.95, 67.55]
5.00 [1.24, 20.09]
13.00 [0.76, 223.14]
2.59 [1.77, 3.79]

410

24289 100.0%

2.62 [1.68, 4.07]

827
Total events
41
Heterogeneity: Tau² = 0.03; Chi² = 3.32, df = 3 (P = 0.35); I² = 10%
Test for overall effect: Z = 4.28 (P < 0.0001)

Risk Ratio
M-H, Random, 95% CI

0.01

0.1
1
10
Favours BMI>50 Favours BMI<25

Figure 2-2: Reoperation Rates Across Severely, Morbidly, and Super-Obese
Patients

100

26

BMI>3524
Study or Subgroup
McLaughlin et. al. 2006

BMI>35
BMI<25
Risk Ratio
Events Total Events Total Weight M-H, Random, 95% CI
14

Total (95% CI)

30

22

30

Total events
14
Heterogeneity: Not applicable
Test for overall effect: Z = 1.55 (P = 0.12)

33 100.0%

0.70 [0.45, 1.10]

33 100.0%

0.70 [0.45, 1.10]

Risk Ratio
M-H, Random, 95% CI
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0.01

0.1
1
10
Favours BMI>35 Favours BMI<25

100

BMI>4026–31
Study or Subgroup

BMI>40
BMI 18.5-25
Risk Ratio
Events Total Events Total Weight M-H, Random, 95% CI
0
3
0
8
5
4

Andrew et. al. 2007
Chee et. al. 2010
Lehman et. al. 1994
McCalden et. al. 2011
Murgatroyd et. al. 2014
Traina et. al. 2011

18
55
8
206
219
187

12
0
13
17
17
126

693

Total (95% CI)

1069 3.3%
55 3.0%
142 3.4%
647 37.6%
1136 26.3%
6102 26.4%

2.25 [0.14, 36.68]
7.00 [0.37, 132.40]
0.59 [0.04, 9.12]
1.48 [0.65, 3.37]
1.53 [0.57, 4.09]
1.04 [0.39, 2.77]

9151 100.0%

1.40 [0.84, 2.32]

185
20
Total events
Heterogeneity: Tau² = 0.00; Chi² = 2.06, df = 5 (P = 0.84); I² = 0%
Test for overall effect: Z = 1.29 (P = 0.20)

Risk Ratio
M-H, Random, 95% CI

0.01

0.1
1
10
Favours BMI>40 Favours BMI<25

100

BMI>5010,12–14
Study or Subgroup
Arsoy et. al. 2014
Issa et. al. 2013
Issa et. al. 2016
Rajgopal et. al. 2013
Total (95% CI)

BMI>50
BMI<30
Risk Ratio
Events Total Events Total Weight M-H, Random, 95% CI
4
1
3
2

42
23
45
39
126

6
0
3
0

84
46
135
39

56.8%
0.0%
34.0%
9.2%

1.33 [0.40, 4.47]
5.88 [0.25, 138.84]
3.00 [0.63, 14.34]
5.00 [0.25, 100.89]

258 100.0%

1.98 [0.80, 4.94]

Total events
9
9
Heterogeneity: Tau² = 0.00; Chi² = 1.05, df = 2 (P = 0.59); I² = 0%
Test for overall effect: Z = 1.47 (P = 0.14)
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Figure 2-3: Aseptic Revisions Rates Across Severely, Morbidly, and Super-Obese
Patients
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Figure 2-4: Septic Revision Rates Across Severely, Morbidly, and Super-Obese
Patients.

100

100

28

BMI>355,22,39–43
*For the super-obese analysis, an earlier study by Issa et. al. (2013)14 is included in the
table, but not used for the pooled calculations. A more recent paper on the same patient
population by Issa et. al. (2016)12 was used for pooled calculations.
Study or Subgroup

Std. Mean Difference

SE

0.0974
0.0195
-0.3193
-0.0788
0.1106
0.0344
0.2497
0.0516

0.054
0.061
0.2261
0.0885
0.1181
0.0808
0.2381
0.1651

Jameson et. al. 2014-1
Jameson et. al. 2014-2
Jones et. al.. 2012
Judge et. al. 2014
Lash et. al. 2013
McLawhorn et. al. 2016
Michalka et. al. 2012
Stickles et. al. 2001

BMI>35 BMI<25
Std. Mean Difference
Total Total Weight IV, Random, 95% CI
428
321
32
150
81
186
21
51
1270

Total (95% CI)

33.0%
25.9%
1.9%
12.3%
6.9%
14.8%
1.7%
3.5%

0.10 [-0.01, 0.20]
0.02 [-0.10, 0.14]
-0.32 [-0.76, 0.12]
-0.08 [-0.25, 0.09]
0.11 [-0.12, 0.34]
0.03 [-0.12, 0.19]
0.25 [-0.22, 0.72]
0.05 [-0.27, 0.38]

6032 100.0%

0.04 [-0.02, 0.10]

1738
1640
52
864
629
865
113
131

Heterogeneity: Tau² = 0.00; Chi² = 6.71, df = 7 (P = 0.46); I² = 0%
Test for overall effect: Z = 1.30 (P = 0.19)

Std. Mean Difference
IV, Random, 95% CI

-0.5 -0.25 0 0.25 0.5
Favours BMI<25 Favours BMI>35

BMI>405,26,34,35,40,43–45
Study or Subgroup
Andrew et. al. 2007
Bennett et. al. 2010
Chee et. al. 2010
Dowsey et. al. 2010
Foster et. al. 2015
Judge et. al. 2010
Judge et. al. 2014
McCalden et. al. 2011
McLawhorn et. al. 2016
Stickles et. al. 2001

Std. Mean Difference

SE

-0.318
0.0509
-0.2189
-0.2103
0.1622
1.0692
0.1129
0.748
0.2441
0.2348

0.2607
0.2627
0.1913
0.2265
0.2317
0.3056
0.1498
0.082
0.122
0.2118

Total (95% CI)

BMI>40 BMI 18.5-25
Std. Mean Difference
Total
Total Weight IV, Random, 95% CI
15
29
55
21
20
11
47
206
73
27
504

795
29
55
277
274
623
864
647
865
131

8.9%
8.8%
10.3%
9.6%
9.5%
7.9%
11.2%
12.3%
11.7%
9.9%

-0.32 [-0.83, 0.19]
0.05 [-0.46, 0.57]
-0.22 [-0.59, 0.16]
-0.21 [-0.65, 0.23]
0.16 [-0.29, 0.62]
1.07 [0.47, 1.67]
0.11 [-0.18, 0.41]
0.75 [0.59, 0.91]
0.24 [0.00, 0.48]
0.23 [-0.18, 0.65]

4560 100.0%

0.19 [-0.08, 0.46]

Heterogeneity: Tau² = 0.15; Chi² = 56.12, df = 9 (P < 0.00001); I² = 84%
Test for overall effect: Z = 1.36 (P = 0.17)

Std. Mean Difference
IV, Random, 95% CI

-0.5 -0.25 0
0.25 0.5
Favours BMI<25 Favours BMI>40

BMI>5010,12,14
Study or Subgroup

Std. Mean Difference

SE

Arsoy et. al. 2014
Issa et. al. 2013
Issa et. al. 2016
Rajgopal et. al. 2013

0.3404
-0.2895
-0.3842
-0.3014

0.2102
0.2566
0.1678
0.2278

Total (95% CI)

BMI>50 BMI<30
Std. Mean Difference
Total Total Weight IV, Random, 95% CI
33
23
48
39

75 32.6%
46
144 36.2%
39 31.1%

0.34 [-0.07, 0.75]
Not estimable
-0.38 [-0.71, -0.06]
-0.30 [-0.75, 0.15]

120

258 100.0%

-0.12 [-0.57, 0.33]

Heterogeneity: Tau² = 0.12; Chi² = 7.83, df = 2 (P = 0.02); I² = 74%
Test for overall effect: Z = 0.53 (P = 0.60)

Std. Mean Difference
IV, Random, 95% CI

-1
-0.5
0
0.5
1
Favours BMI<25 Favours BMI>50

Figure 2-5: Change Scores for Outcome Across Severely, Morbidly, and SuperObese Patients
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For risk of reoperations relative to the non-obese cohort, we found that there was an
increased relative risk for the morbidly (2.01, 95% CI: 1.81-2.23, p<0.01) and superobese patients (2.62, 95% CI: 1.68-4.07, p<0.01) (Figure 2-2). The increased risk of
reoperation for the severely-obese was not significant (1.40, 95% CI: 0.97-2.02, p=0.07).
Exclusion of studies with short-term (less than a year) follow-up did not change the
significance of the results for the severely-obese (1.24, 95% CI: 0.68-2.26, p=0.49) or
super-obese (3.57, 95% CI: 1.33-9.57, p=0.01). In the case of the morbidly-obese, the
increased risk was no longer significant (1.50, 95% CI: 0.93-2.41, p=0.10). Both the
morbidly and super-obese patient comparisons had no heterogeneity with I2 = 0% and
10%, respectively, the heterogeneity had minimal change with the sensitivity analysis.
Between study heterogeneity was not reduced with sensitivity analysis for the severelyobese patient comparison (I2 = 83% and I2 = 82% for the longer follow-up studies only).
Aseptic revision was only reported in one study for the severely-obese patients (Figure 23). That study did not show any increased risk for the severely-obese patients (0.70, 95%
CI: 0.45-1.10, p=0.12), but each group only had about 30 patients. Similarly, there was
no significantly increased risk of aseptic revisions for either the morbidly (1.40, 95% CI:
0.84-2.32, p=0.20) or super-obese (1.98, 95% CI: 0.80-4.94, p=0.14) patients. All studies
for both the morbidly and super-obese patients included longer follow-up so no additional
sensitivity analysis was performed for this outcome. There was no heterogeneity (I2 =
0%) for either the morbidly or super-obese analysis.
The risk of septic revisions were found to be significantly higher for severely (3.17, 95%
CI: 2.25-4.47, p<0.01), morbidly (9.75, 95% CI: 3.58--26.59, p<0.01), and super-obese
patients (7.22, 95% CI: 1.51-34.60, p=0.01) (Figure 2-4). Sensitivity analysis could not
be performed for the severely or super-obese patients, since all included studies had
follow-up of one year or greater. After removal of the studies with short follow-up in the
morbidly-obese patient analysis, the risk ratio was still significantly greater at 7.49 (95%
CI: 3.85-14.57, p<0.01) and the heterogeneity was reduced from 70% to 0%. There was
no heterogeneity (I2 = 0%) with the severely and super-obese analysis.
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The change in functional outcome score as evaluated by standardized mean difference
was not significantly different between the severely (0.04, 95% CI: -0.02-0.10, p=0.19),
morbidly (0.19, 95% CI: -0.08-0.46, p=0.17), and super-obese patients (-0.12, 95% CI: 0.57-0.33 p=0.60) with then non-obese population. Sensitivity analysis focusing on
longer term outcomes of 1 year or more did not alter the results for the severely (0, 95%
CI: -0.10-0.09, p=0.95) or morbidly-obese (0.15, 95% CI: -0.10-0.40, p=0.23). All
studies included for the super-obese analysis had longer term follow up, and two reported
worse improvement and one reported better improvement for the super-obese resulting in
high heterogeneity for this result (I2 = 86%). There was no heterogeneity (I2 = 0%) for the
severely-obese analysis. Sensitivity analysis did not reduce the heterogeneity (I2 = 84%
vs. 86%) for the morbidly-obese analysis.

2.4 Discussion
Our results suggest that both morbidly and super-obese populations are at a higher risk
for reoperation following THA than the non-obese population, with the super-obese at a
higher relative risk than the morbidly obese. All three obese groups were at a higher risk
for septic revision than the non-obese patients, and the morbidly-obese (RR 9.75, 95%
CI: 3.58--26.59, p<0.01) and super-obese (RR 7.22, 95% CI: 1.51-34.60, p=0.01) had a
much higher relative risk than the severely-obese (RR 3.17, 95% CI: 2.25-4.47, p<0.01)
patients. The severely, morbidly, and super-obese patients did not have a significant
difference in aseptic revision or change in functional outcome scores.
Our study did not find a greater risk of reoperation until the BMI reached the morbidly
and super-obese groups. Wagner et al. reported similar results based on their
retrospective study of their institution's outcomes.39 They found no significantly greater
risk of reoperation until a BMI greater than 40, which had a hazard ratio of 1.6 (95% CI:
1.3-2.0) relative to the non-obese. We had a comparable risk ratio of 2.01 (95% CI: 1.812.23) for our morbidly-obese group. For the morbidly-obese deep infection rate, we
reported a greater risk ratio of 9.75 (95% CI: 3.58-26.59) versus Wagner et al.'s hazard
ratio of 4.4 (95% CI: 2.8-6.9).18 The difference in results could be partly attributed to the
varying definitions in deep infection/septic revisions utilized by the studies included in
the meta-analysis. Also, our sensitivity analysis examining longer term follow-up
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demonstrated a slightly lower relative risk ratio that does include Wagner's hazard ratio in
its confidence interval (7.49, 95% CI: 3.85-14.57).
In recent years, there has been an increased focus on preoperative optimization prior to
THA and TKA. It has been controversial whether, and to what degree, obesity can be
reduced, or at least optimized. Some studies have examined the impact of both
nonoperative and operative means of weight loss but their influence on improving
arthroplasty outcomes has not been clearly demonstrated.46 At the same time, there is
clear evidence that obese patients have increased costs of care and complications.47
Consequently, some authors recommend BMI thresholds (35-45) above which an
arthroplasty should not be offered.11,41,48 Our study clearly demonstrates that over the
long term, severely, morbidly, and super-obese patients benefit significantly by having an
arthroplasty with comparable change scores as the non-obese cohorts, although they also
have varying levels of increased risks for reoperation and septic revision. This leads to
the question of whether obese patients should be denied a procedure that provides
significant benefit, despite the additional risks. For other chronic diseases such as
diabetes, we do not deny those patients an arthroplasty. Instead, physicians focus on
improving their glucose management, to optimize their perioperative outcomes.
Unfortunately, there are no clear obesity treatments that have been demonstrated to
improve obesity's perioperative risk profile. This issue will become even more important
with the combined factors of increasing number of obese individuals, increasing degree
of obesity around the world, and changing health care policy.1,47
The limitations in this study are those common with systematic reviews and metaanalysis; the quality of results are limited by the quality of the included studies. We did
perform a quality analysis and found that the predominant study design was retrospective
cohort studies, with only two prospective cohort studies, resulting in a high degree of
either selection or missing data bias. Another limitation included varying follow-up times
that can influence the revision rates. We did account for that in our sensitivity analysis
and found that in only one case did it alter the significance of our results. For the superobese group's change score analysis, we only had three studies with one reporting a
conflicting results. This warrants further research to better evaluate their outcome scores
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after arthroplasty. Some studies did not have a non-obese (BMI 18.5-25) cohort for
comparison, as a result the smallest BMI cohort was chosen for comparison. Since
Wagner et al18 suggested that results only dramatically change above a BMI of 40, this
likely is not an important factor for reoperations since the comparison groups had a BMI
less than or equal to 40 (except for one study in the super-obese group, Arsoy et. al.10,
which used a comparison group with BMI less than 50). The results for septic revision
could be underestimated due to the differences in comparison groups. For the functional
outcome score comparisons, we choose the outcome measures that were most commonly
reported in the included studies, but some studies only reported one outcome measure in
which case that was used.
Older literature tended to categorize all patients with a BMI greater than 30 as obese, and
prior systematic reviews15–17 have used these studies to evaluate the impact of obesity.
However, a more granular evaluation of obesity is warranted since the risk profile of
everyone with a BMI greater than 30 is not the same. This inspired our study to focus on
a systematic review and meta-analysis of the studies that consider the sub-categories of
obesity. In addition, many of the studies on higher obesity categories were limited by
number of patients available, and we hoped to increase the power of our study by pooling
the results of multiple studies in the meta-analysis. We found that severely, morbidly, and
super-obese patients have comparable functional outcome score improvements to nonobese patients, but have higher risk of reoperation and septic revision. The different
obesity thresholds have dramatically different risk profiles that need to be accounted for
in perioperative counseling.

33

2.5 References
1.

WHO :: Global Database on Body Mass Index. Available at:

http://apps.who.int/bmi/index.jsp. (Accessed: 12th February 2017)
2.

Derman, P. B., Fabricant, P. D. & David, G. The Role of Overweight and Obesity

in Relation to the More Rapid Growth of Total Knee Arthroplasty Volume Compared
with Total Hip Arthroplasty Volume. J. Bone Joint Surg. Am. 96, 922–928 (2014).
3.

Bourne, R., Mukhi, S., Zhu, N., Keresteci, M. & Marin, M. Role of obesity on the

risk for total hip or knee arthroplasty. Clin. Orthop. 465, 185–188 (2007).
4.

Leveille, S. G., Wee, C. C. & Iezzoni, L. I. Trends in obesity and arthritis among

baby boomers and their predecessors, 1971-2002. Am. J. Public Health 95, 1607–1613
(2005).
5.

McLawhorn, A. S. et al. Body Mass Index Class Is Independently Associated

With Health-Related Quality of Life After Primary Total Hip Arthroplasty: An
Institutional Registry-Based Study. J. Arthroplasty 32, 143–149 (2017).
6.

Ward, D. T., Metz, L. N., Horst, P. K., Kim, H. T. & Kuo, A. C. Complications of

Morbid Obesity in Total Joint Arthroplasty: Risk Stratification Based on BMI. J.
Arthroplasty 30, 42–46 (2015).
7.

Wallace, G. et al. The effect of body mass index on the risk of post-operative

complications during the 6 months following total hip replacement or total knee
replacement surgery. Osteoarthritis Cartilage 22, 918–927 (2014).
8.

Werner, B. C., Higgins, M. D., Pehlivan, H. C., Carothers, J. T. & Browne, J. A.

Super Obesity Is an Independent Risk Factor for Complications After Primary Total Hip
Arthroplasty. J. Arthroplasty 32, 402–406 (2017).
9.

Maradit Kremers, H., Visscher, S. L., Kremers, W. K., Naessens, J. M. &

Lewallen, D. G. Obesity increases length of stay and direct medical costs in total hip
arthroplasty. Clin. Orthop. 472, 1232–1239 (2014).

34

10.

Arsoy, D., Woodcock, J. A., Lewallen, D. G. & Trousdale, R. T. Outcomes and

complications following total hip arthroplasty in the super-obese patient, BMI > 50. J.
Arthroplasty 29, 1899–1905 (2014).
11.

Schwarzkopf, R., Thompson, S. L., Adwar, S. J., Liublinska, V. & Slover, J. D.

Postoperative complication rates in the ‘super-obese’ hip and knee arthroplasty
population. J. Arthroplasty 27, 397–401 (2012).
12.

Issa, K. et al. Bariatric Orthopaedics: Total Hip Arthroplasty in Super-Obese

Patients (Those with a BMI of ≥50 kg/m2). J. Bone Joint Surg. Am. 98, 180–185 (2016).
13.

Rajgopal, R. et al. Outcomes and complications of total hip replacement in super-

obese patients. Bone Jt. J. 95–B, 758–763 (2013).
14.

Issa, K. et al. Early results of total hip arthroplasty in the super-obese patients. J.

Long. Term Eff. Med. Implants 23, 309–313 (2013).
15.

Haynes, J., Nam, D. & Barrack, R. L. Obesity in total hip arthroplasty: does it

make a difference? Bone Jt. J. 99–B, 31–36 (2017).
16.

Liu, W. et al. The influence of obesity on primary total hip arthroplasty outcomes:

A meta-analysis of prospective cohort studies. Orthop. Traumatol. Surg. Res. OTSR 101,
289–296 (2015).
17.

Vincent, H. K. et al. Obesity and long term functional outcomes following

elective total hip replacement. J. Orthop. Surg. 7, 16 (2012).
18.

Wagner, E. R., Kamath, A. F., Fruth, K. M., Harmsen, W. S. & Berry, D. J. Effect

of Body Mass Index on Complications and Reoperations After Total Hip Arthroplasty. J.
Bone Joint Surg. Am. 98, 169–179 (2016).
19.

McGinn, T. et al. Tips for learners of evidence-based medicine: 3. Measures of

observer variability (kappa statistic). CMAJ Can. Med. Assoc. J. 171, 1369–1373 (2004).

35

20.

ROBINS-I tool - Risk of bias tools. Available at:

http://www.riskofbias.info/welcome/home. (Accessed: 23rd June 2017)
21.

Fu, M. C. et al. Malnutrition Increases With Obesity and Is a Stronger

Independent Risk Factor for Postoperative Complications: A Propensity-Adjusted
Analysis of Total Hip Arthroplasty Patients. J. Arthroplasty 31, 2415–2421 (2016).
22.

Jameson, S. S. et al. The impact of body mass index on patient reported outcome

measures (PROMs) and complications following primary hip arthroplasty. J.
Arthroplasty 29, 1889–1898 (2014).
23.

Khatod, M., Cafri, G., Namba, R. S., Inacio, M. C. S. & Paxton, E. W. Risk

factors for total hip arthroplasty aseptic revision. J. Arthroplasty 29, 1412–1417 (2014).
24.

McLaughlin, J. R. & Lee, K. R. The outcome of total hip replacement in obese

and non-obese patients at 10- to 18-years. J. Bone Joint Surg. Br. 88, 1286–1292 (2006).
25.

Purcell, R. L., Parks, N. L., Gargiulo, J. M. & Hamilton, W. G. Severely Obese

Patients Have a Higher Risk of Infection After Direct Anterior Approach Total Hip
Arthroplasty. J. Arthroplasty 31, 162–165 (2016).
26.

Andrew, J. G. et al. Obesity in total hip replacement. J. Bone Joint Surg. Br. 90,

424–429 (2008).
27.

Chee, Y. H., Teoh, K. H., Sabnis, B. M., Ballantyne, J. A. & Brenkel, I. J. Total

hip replacement in morbidly obese patients with osteoarthritis: results of a prospectively
matched study. J. Bone Joint Surg. Br. 92, 1066–1071 (2010).
28.

Lehman, D. E., Capello, W. N. & Feinberg, J. R. Total hip arthroplasty without

cement in obese patients. A minimum two-year clinical and radiographic follow-up
study. J. Bone Joint Surg. Am. 76, 854–862 (1994).
29.

McCalden, R. W., Charron, K. D., MacDonald, S. J., Bourne, R. B. & Naudie, D.

D. Does morbid obesity affect the outcome of total hip replacement?: an analysis of 3290
THRs. J. Bone Joint Surg. Br. 93, 321–325 (2011).

36

30.

Murgatroyd, S. E., Frampton, C. M. A. & Wright, M. S. The effect of body mass

index on outcome in total hip arthroplasty: early analysis from the New Zealand Joint
Registry. J. Arthroplasty 29, 1884–1888 (2014).
31.

Traina, F., Bordini, B., De Fine, M. & Toni, A. Patient weight more than body

mass index influences total hip arthroplasty long term survival. Hip Int. J. Clin. Exp. Res.
Hip Pathol. Ther. 21, 694–699 (2011).
32.

Namba, R. S., Inacio, M. C. S. & Paxton, E. W. Risk factors associated with

surgical site infection in 30,491 primary total hip replacements. J. Bone Joint Surg. Br.
94, 1330–1338 (2012).
33.

Namba, R. S., Paxton, L., Fithian, D. C. & Stone, M. L. Obesity and perioperative

morbidity in total hip and total knee arthroplasty patients. J. Arthroplasty 20, 46–50
(2005).
34.

Bennett, D., Gibson, D., O’Brien, S. & Beverland, D. E. Hip arthroplasty in

morbidly obese patients - intra-operative and short term outcomes. Hip Int. J. Clin. Exp.
Res. Hip Pathol. Ther. 20, 75–80 (2010).
35.

Dowsey, M. M., Liew, D., Stoney, J. D. & Choong, P. F. M. The impact of

obesity on weight change and outcomes at 12 months in patients undergoing total hip
arthroplasty. Med. J. Aust. 193, 17–21 (2010).
36.

Hanly, R. J., Marvi, S. K., Whitehouse, S. L. & Crawford, R. W. Morbid Obesity

in Total Hip Arthroplasty: Redefining Outcomes for Operative Time, Length of Stay, and
Readmission. J. Arthroplasty 31, 1949–1953 (2016).
37.

Jibodh, S. R., Gurkan, I. & Wenz, J. F. In-hospital outcome and resource use in

hip arthroplasty: influence of body mass. Orthopedics 27, 594–601 (2004).
38.

Walls, J. D. et al. Hypoalbuminemia More Than Morbid Obesity is an

Independent Predictor of Complications After Total Hip Arthroplasty. J. Arthroplasty 30,
2290–2295 (2015).

37

39.

Lash, H., Hooper, G., Hooper, N. & Frampton, C. Should a Patients BMI Status

be Used to Restrict Access to Total Hip and Knee Arthroplasty? Functional Outcomes of
Arthroplasty Relative to BMI - Single Centre Retrospective Review. Open Orthop. J. 7,
594–599 (2013).
40.

Jones, C. A., Cox, V., Jhangri, G. S. & Suarez-Almazor, M. E. Delineating the

impact of obesity and its relationship on recovery after total joint arthroplasties.
Osteoarthritis Cartilage 20, 511–518 (2012).
41.

Judge, A. et al. Body mass index is not a clinically meaningful predictor of

patient reported outcomes of primary hip replacement surgery: prospective cohort study.
Osteoarthritis Cartilage 22, 431–439 (2014).
42.

Michalka, P. K. R. et al. The influence of obesity on early outcomes in primary

hip arthroplasty. J. Arthroplasty 27, 391–396 (2012).
43.

Stickles, B., Phillips, L., Brox, W. T., Owens, B. & Lanzer, W. L. Defining the

relationship between obesity and total joint arthroplasty. Obes. Res. 9, 219–223 (2001).
44.

Foster, S. A. et al. Effects of Obesity on Health Related Quality of Life Following

Total Hip Arthroplasty. J. Arthroplasty 30, 1551–1554 (2015).
45.

Judge, A., Cooper, C., Williams, S., Dreinhoefer, K. & Dieppe, P. Patient-

reported outcomes one year after primary hip replacement in a European Collaborative
Cohort. Arthritis Care Res. 62, 480–488 (2010).
46.

WHO :: Global Database on Body Mass Index. Available at:

http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. (Accessed: 12th February
2017)
47.

Inacio, M. C. S. et al. The impact of pre-operative weight loss on incidence of

surgical site infection and readmission rates after total joint arthroplasty. J. Arthroplasty
29, 458–464.e1 (2014).

38

48.

Comprehensive Care for Joint Replacement Model | Center for Medicare &

Medicaid Innovation. Available at: https://innovation.cms.gov/initiatives/CJR.
(Accessed: 12th February 2017)
49.

Lübbeke, A. et al. Body mass and weight thresholds for increased prosthetic joint

infection rates after primary total joint arthroplasty. Acta Orthop. 87, 132–138 (2016).

39

Chapter 3

3

90-Day Costs, Reoperations, and Readmissions for
Primary Total Hip Arthroplasty Patients of Varying BMI
Levels

3.1 Introduction
The demand for total hip arthroplasty (THA) is increasing rapidly due to a combination
of an aging population as well as an increasing level of obesity in the US and Canada.1,2
Patients with a higher BMI may be at a greater risk for perioperative length of stay,
complications, infections, and revision.3–5 Nonetheless, obese patients who undergo a
THA report significant improvements in pain, function, and activity levels after the
procedure.6–8 Concurrently, in the United States several payers for health care including
both government (Medicare) and private insurance are instituting bundled payment plans
where physicians and hospitals will be held financially accountable for complications
within 90-days of a surgery.9 Similarly, many of the Canadian provincial healthcare
systems have fixed budgets to perform a government established number of THAs. The
costs of any subsequent readmission or revision as a complication of the index procedure
are absorbed by the treating hospital. Additionally, metrics such as 30-day readmissions,
infections and reoperation within a year are used to track hospital quality. It is
conceivable that Canadian hospitals could be penalized for underperforming outcome
metrics which are actually a reflection of the case acuity. When a center's quality of care
is assessed, no metric to account for taking care of a greater number of high risk patients
(such as obesity) is utilized. In both countries, many providers have arbitrarily chosen
specific body mass index (BMI) levels ranging from 35-45, above which they will not
offer arthroplasty as an option.
Health care policy incentivizes a focus on the short-term outcomes and their economic
implications and does not account for the longer-term benefits. Prior studies have focused
on either the costs10 or complications11–13, or on the functional outcomes8 for different
BMIs. We sought to more thoroughly evaluate both the risks and the benefits of
arthroplasty for a wide range of BMIs, which can provide guidance for clinicians,
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patients and administrators to ensure optimal care for obese and non-obese arthritic
patients.
The primary purpose of this study is to compare 90-day costs and mid-term functional
score improvements following total hip arthroplasty (THA) among non-obese (BMI 18.524.9), overweight (25-29.9), obese (30-34.9), severely-obese (35-39.9), morbidly-obese
(40-44.9), and super-obese (45+) patient cohorts. We hypothesized that the 90-day costs
would be higher for the super-obese patient population, but that those patients would
have comparable functional score improvements relative to the other BMI groups.

3.2 Methods
We retrospectively reviewed our institutional database to identify patients who had
undergone a primary THA between 2006 and 2013. Data was collected at the beginning
of 2017. All patients who had a unilateral primary THA (with an underlying diagnosis of
osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, or osteonecrosis) were
included for selection into the study. Patients who had a simultaneous bilateral
arthroplasty, acute fracture or polytrauma as indication for arthroplasty, femoral
shortening osteotomy, or skeletal dysplasia were excluded from the study. BMI was
calculated from heights and weights measured at the preoperative assessment and
recorded in the database. The patients were categorized into 6 groups based on BMI
recorded in the database: <25 (non-obese), 25-29.9 (overweight), 30-34.9 (obese), 3539.9 (severely-obese), 40-44.9 (morbidly-obese), and 45+ (super-obese). We used a
sample of convenience based on the number of eligible patients in the super-obese
category, as this was expected to be the least common. We identified 33 patients with a
BMI categorized as super-obese and met the inclusion and exclusion criteria. Patients
from the other BMI cohorts were then selected randomly from the entire THA cohort by
use of a random numbers table in a 2:1 ratio relative to the super-obese cohort (66
patients in each group, total of 363 patients). Perioperative protocols were the same for
all BMI cohorts except for DVT prophylaxis. Low molecular weight heparin was used for
DVT prophylaxis for the morbidly and super-obese patients, and aspirin was used for the
other cohorts.
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3.2.1

Outcome Measures

Patient charts and electronic medical records were reviewed. We extracted demographic
variables including age, sex, BMI, smoking status, Charlson comorbidity index (CCI),
and American Society of Anesthesiologists (ASA) score. We also recorded all in-hospital
resource use such as time in the operating room, anesthesia type, length of hospital stay,
and perioperative complications (DVT/PE and superficial infection). For the first 90-days
postoperative, we identified emergency room visits, reoperations, and readmissions to
hospitals within the local region (most hospitals within a 100 kilometer radius of our
institution). Medical records were reviewed to identify mid-term revisions rates
(reoperation for any cause, aseptic, and septic revision). Costs were determined using unit
costs from our institutional administrative data for all in-hospital resource utilization
(Table 3-1). Costs for the index hospitalization, 90-day readmissions, and 90-day ER
visits were averaged over all patients whether or not they had a readmission or ER visit.
The 90-day costs were calculated by taking the sum of the index hospitalization, 90-day
readmissions, and 90-day ER visits.
Table 3-1: Unit Costs from Administrative Data
Item

Costs
Inpatient

PACU Stay
Inpatient Costs (per hour)
Inpatient Meals (per hour)
PT cost (per hour)
OT cost
Average Consults
Average Transfusion
Average Lab & Imaging
Pelvis X-Ray
Antibiotics & Foley

$344.10
$26.13/hr
$1.40/hr
$2.47/hr
$92.22
$78.85
$6.84
$53.12
$95.13
$18.73
Operating Room

OR Time (per min)
Anesthesia Equipment
Average OR Packs
Acetabular Socket
Femoral Stem
Femoral Head
Liner
Screw
Luque Wire

$16.37/min
$269.04
$318.59
$500.00
$950.00
$200.00
$800.00
$75.00
$43.26
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We also collected patient-reported outcome measures from the database. All patients
treated at our institution complete the Harris Hip Score (HHS), Short-Form Health
Survey (SF-12), and Western Ontario and McMaster Universities Arthritis Index
(WOMAC) preoperatively and at each visit postoperatively. We used the preoperative
and latest postoperative data to calculate a change score for each patient. Scores were
scaled such that lower scores meant worse function and higher scores meant greater
function. Missing data due to inadequate recording in the patient chart or incomplete
outcome questionnaires were not included in statistical analysis. The primary outcomes
of interest were 90-day costs and midterm change scores. Secondary outcomes are
perioperative outcomes, 90-day complications, and midterm (3 year) revision rates.

3.2.2

Statistical Analysis

We used descriptive statistics (frequencies, means and standard deviation) to summarize
the demographics, clinical characteristics, and outcomes. For continuous variables,
normality was tested with the Shapiro-Wilk test. Normally distributed continuous
variables were compared using analysis of variance (ANOVA) and non-normal
continuous variables were compared using the nonparametric Kruskal-Wallis H test.
Significance on these tests implied that there was a statistically significant difference
across all six cohorts. A post-hoc Tukey's test was performed on variables that
demonstrated a significant difference on ANOVA to identify the specific BMI cohort
comparisons that led to the statistical difference. Categorical variables were compared
with either a Chi Square analysis or Fisher’s exact test. Statistical significance was set at
p < 0.05. Data were analyzed using Stata, Version 12, Software (Stata Corp LP, College
Station, TX).
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3.3 Results
3.3.1

Demographics

Table 3-2: Demographics of THA Patients by BMI Group
Variable
18.5-24.9
NonObese
(n = 66)
Age
(mean±standard
deviation)
66.7±12.9
Sex (%Female)
69.7
BMI
(mean±standard
deviation)
22.2±2.3
Charlson
Comorbidity
Index (CCI) (%)
0
69.7
1
22.7
2
4.5
3
3.0
4
0.0
5
0.0
American
Society of
Anesthesiologists
Score (ASA) (%)
1
7.6
2
45.5
3
39.4
4
7.6
Smoking (%)
16.7

Body Mass Index (BMI) Group
35-39.9
40-44.9
25-29.9
30-34.9 Severely- MorbidlyOverweight
Obese
Obese
Obese
(n = 66)
(n = 66)
(n = 66)
(n = 66)

45+
SuperObese
(n = 33) p-value

68.2±11.1 65.2±12.1 62.8±12.1 59.0±10.7 57.1±9.1 <0.01
65.2
45.5
56.1
71.2
66.7 0.02
27.4±1.3

32.2±1.3

37.2±1.3

42.3±1.4 50.0±4.5 <0.01

62.1
25.8
3.0
6.1
0.0
3.0

69.7
22.7
7.6
0.0
0.0
0.0

69.7
18.2
7.6
3.0
1.5
0.0

54.5
34.8
10.6
0.0
0.0
0.0

57.6
24.2
6.1 0.03
6.1
6.1
0.0

4.5
45.5
47.0
3.0
9.1

1.5
50.0
43.9
4.5
7.6

3.0
28.8
60.6
7.6
9.1

1.5
15.2
75.8
7.6
7.6

3.0
6.1 <0.01
57.6
33.3
3.0 0.31

The demographics of the study participants are reported in Table 3-2. There was a
statistically significant difference in age across the groups (p < 0.01). In particular, the
morbidly and super-obese patients were significantly younger than the non-obese (p <
0.01 and p < 0.01, respectively), overweight (p < 0.01 and p < 0.01, respectively), and
obese groups (p = 0.03 and p = 0.02, respectively). There were significant differences in
CCI (p = 0.03) and ASA (p < 0.01) across the BMI groups. The higher BMI categories
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had more patients with ASA scores of 3 and 4 than 1 and 2. No significant difference was
found in smoking rates across the BMI cohorts (p = 0.31).

3.3.2

Primary Outcomes

90-Day Costs ($ CAD)

25000
20000
15000
10000
5000
0
18.5-24.9

25.0-29.9

30-34.9
35-39.9
BMI Cohort

40-44.9

45+

Figure 3-1: 90-Day Costs Across BMI Cohorts
At 90-days, the costs were significantly different across the BMI cohorts (p < 0.01)
(Figure 3-1). The super-obese cohort had significantly greater costs than the four smallest
BMI cohorts (p < 0.01 for every comparison) but not relative to the morbidly-obese (p =
0.23). The morbidly-obese cohort had significantly higher costs than the non-obese (p =
0.03) and the severely obese (p = 0.04) cohort. The inpatient costs were significantly
different across the BMI cohorts (p < 0.01), and the difference in magnitude between the
super-obese and the non-obese cohorts is approximately $1,700. By 90-days, the cost
differential between the super-obese and the non-obese cohorts is approximately $5,300.
The main three contributors to the cost differential are readmissions, index
hospitalization, and treatment with fragmin for DVT prophylaxis. For HHS, SF12 MCS
and PCS, and WOMAC, there were no significant differences in change scores across the
BMI cohorts (p = 0.29, p = 0.47, p = 0.86, and p = 0.93, respectively).
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3.3.3

Secondary Outcomes

Perioperative outcomes during the inpatient stay, 90-days, and after 3 years are reported
in Table 3-3. The time in the operating room was significantly different among the BMI
cohorts (p < 0.01). Post-hoc analysis demonstrated that the super-obese had significantly
longer operative time compared to all other BMI cohorts (p < 0.01, p < 0.01, p < 0.01, p =
0.01, and p = 0.01, respectively for the non-obese to morbidly-obese). The severely-obese
and morbidly-obese had significantly longer operative time than the non-obese cohort (p
= 0.01 and p = 0.01, respectively). There was no statistically significant difference among
the BMI cohorts for length of hospital stay. At 90-days, there were no significant
differences in the superficial infection (p = 0.14), VTE (p = 0.71), ER visits (p = 0.06), or
readmissions (p = 0.05) across all the BMI cohorts. Ninety day reoperation rates were
significantly different among the BMI cohorts (p < 0.01) with the morbidly and superobese patients having dramatically more reoperations of any kind.
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Table 3-3: Outcomes of THA Patients by BMI Group
Variable
18.5-24.9
Non25-29.9
Obese
Overweight
(n = 66)
(n = 66)
Outcomes During Hospitalization
OR Time (min)
(mean±standard
deviation)
119±19
122±22
Anesthesia
Spinal
72.7%
50.0%
General
27.3%
50.0%
Other
0.0%
0.0%
LOS (days)
(mean±standard
deviation)
4.4±1.7
4.3±1.5
Discharge to
Extended Care
Facility
16.7%
12.1%
Inpatient Cost
(mean±standard
$10,002
$10,000
deviation)
±1,348
±1,265
Outcomes at 90 Days
Superficial
Infection
3.0%
7.6%
VTE
0.0%
1.5%
ER Visit
12.1%
19.7%

BMI Group
35-39.9
30-34.9
SeverelyObese
Obese
(n = 66)
(n = 66)

40-44.9
MorbidlyObese
(n = 66)

45+
Super-Obese
(n = 33) p-value

129±24

133±29

132±20

150±28 <0.01

68.2%
30.3%
1.5%

62.1%
36.4%
1.5%

63.6%
36.4%
0.0%

60.6% 0.27
39.4%
0.0%

4.8±2.5

4.2±2.0

4.6±2.0

5.6±3.5 0.06

12.1%

13.6%

15.2%

18.2% 0.95

$10,392
±1,797

$10,102
±1,772

$10,615
±1,547

3.0%
3.0%
16.7%

4.5%
3.0%
9.1%

13.6%
3.0%
16.7%

$11,704
±2,997 <0.01

9.1% 0.14
0.0% 0.71
33.3% 0.06
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Table 3-3 (continued): Outcomes of THA Patients by BMI Group
Readmission
4.5%
4.5%
6.1%
3.0%
7.6%
21.2% 0.05
Reoperation
0.0%
4.5%
1.5%
1.5%
6.1%
18.2% <0.01
ER Costs
(mean±standard
deviation)
$83±240
$158±401
$113±286
$68±229
$128±373
$211±352 0.27
Readmission
Costs
(mean±standard
deviation)
$226±1110 $1,230±6,610 $641±3,711 $275±1,905 $1,399±6,796 $2,697±6,018 0.15
Cost (including
index
hospitalization)
(mean±standard
$10,315
$11,392
$11,150
$10,449
$13,134
$15,604
deviation)
±1,848
±6,936
±4,225
±2,119
±7,250
±6,783 <0.01
Outcomes after 3 Years
Mortality
3.0%
1.5%
7.6%
1.5%
1.5%
9.1% 0.14
Reoperation
Cumulative
from Index
surgery
3.0%
4.5%
4.5%
4.5%
10.6%
21.2% 0.03
Aseptic
Revision
1.5%
1.5%
3.0%
3.0%
1.5%
6.1% 0.74
Septic Revision
1.5%
3.0%
1.5%
1.5%
7.6%
18.2% <0.01
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Table 3-4: Functional Outcome Scores of THA Patients by BMI Group
Variable

BMI Group

(mean±standard
deviation)
HHS
Preoperative
Postoperative
Change
SF12 MCS
Preoperative
Postoperative
Change
SF12 PCS
Preoperative
Postoperative
Change
WOMAC
Preoperative
Postoperative
Change

18.524.9
Non25-29.9
Obese Overweight
(n = 66)
(n = 66)

35-39.9
40-44.9
45+
30-34.9 Severely- Morbidly- SuperObese
Obese
Obese
Obese
(n = 66)
(n = 66)
(n = 66) (n = 33) p-value

54±11
95±7
40±12

46±12
92±10
44±15

50±10
91±12
40±16

44±12
87±16
44±20

42±12
88±12
49±14

39±17 <0.01
84±14 <0.01
40±17 0.29

51±11
54±9
3±13

51±10
55±8
4±8

53±11
54±10
1±12

49±12
52±10
2±12

48±12
52±11
6±13

46±12 0.06
49±14 0.06
3±14 0.47

31±9
43±12
12±13

29±8
40±12
12±12

29±8
41±12
11±12

29±7
39±11
11±12

27±6
37±13
9±12

25±6 <0.01
35±10 0.01
11±10 0.86

43±18
85±18
41±23

40±16
76±23
37±23

42±18
83±18
40±24

39±14
76±22
38±25

36±16
73±22
37±25

35±15 0.11
70±23 <0.01
39±24 0.93

Outcomes after 3 years demonstrated no significant difference in mortality (p = 0.14) or
aseptic revisions across the cohorts (p = 0.74). Reoperation (p = 0.03) and septic revision
(p < 0.01) rates were significantly different across the BMI cohorts. The super-obese had
greater cumulative reoperation and septic revision rates compared to the non-obese
cohort (21.2% vs 3.0%, p = 0.01 and 18.2% vs 1.5%, p = 0.01, respectively).

3.4 Discussion
Obesity is not a simple binary comorbidity that can be evaluated as being above or below
a BMI of 30. The degree of obesity plays an influential role in the risk of perioperative
complications and costs of care. Given that health policy in many healthcare systems in
the developed world, including both the United States and Canada, focus on the shortterm costs (such as 90-days), one of our primary objectives was to focus on the 90-day
costs of care for various BMI cohorts. We found that in the short-term, 90-day costs were
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much higher for the morbidly-obese (>25% higher) and super-obese (>50%) cohorts than
the non-obese cohort. The focus on the short-term risks should not divert attention from
the potential mid-term benefits and they need to be stratified by BMI as well. We found
that the change scores for HHS, SF12 MCS and PCS, and WOMAC were comparable
across all BMI cohorts.
Our costing analysis was based on the costs at a Canadian hospital, which generally has
lower costs compared to the United States healthcare systems. Kremers et al. also
reported their costs in the United States across multiple BMI cohorts and found that costs
were relatively stable for BMIs ranging from 18.5 to 40, but above 40 the costs started to
increase.10 The cost of their non-obese group at 90-days postoperative was approximately
$20,000. Our results for the non-obese cohort were half as much, largely owing to the
lower costs of care in Canada. We also found a more dramatic increase in the costs for
the morbidly-obese and super-obese of 25-50% over the non-obese, while Kremers et
al.10 had only a 5-10% premium for the same cohorts relative to the non-obese. In our
study, the three main factors driving the increased costs were readmissions, index
hospitalization, and DVT prophylaxis differences. Kremers et al.10 did not report the
readmission rate or differences in DVT prophylaxis for their BMI cohorts. Our study had
a 90-day reoperation rate of 6.1% in the morbidly-obese and 18.2% in the super-obese
cohorts. Our readmission rates are comparable to those reported in the literature. In a
meta-analysis, Ramkumar et al.17 reported a 90-day readmission rate of 7.7% after a
THA. Our readmission rates were lower than that for all BMI groups with the exception
of the super-obese cohort.
We also found that the degree of improvement in outcome scores were comparable across
the BMI cohorts. McLawhorn et al. examined EQ-5D scores (a measure of health status
utility, frequently used for cost-effectiveness) across different BMI cohorts and reported
that their larger BMI cohorts had comparable or greater improvements than their nonobese cohort.8 Other studies report that the various obesity categories (ranging from
severely-obese to super-obese) have comparable outcome score improvements as nonobese cohorts.4,6,7,14–16 The potential for greater improvement in higher obesity classes
may be due to their lower preoperative scores. Surgeons may delay surgical intervention
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for the morbidly and super-obese patients because of their BMI. During the time it takes
for these patients to identify a surgeon willing to perform their procedure, their function
may deteriorate leading to a lower preoperative score than a patient who is at a lower
obesity level. Consequently, an arthroplasty may lead to a larger improvement in
outcome.
Our study had a much higher risk for revision than was reported by Wagner et al.3 They
reported a hazard ratio of 1.6 for reoperation for the BMI>40 cohort versus the BMI 18.525 cohort, and no significant difference in risk for reoperation for other obese categories
with a BMI<40. Similarly, we found no significant difference in reoperation in the
overweight, obese, and severely-obese cohorts versus the non-obese cohort. Compared to
the non-obese, our relative risk was greater in the morbidly-obese by over three times and
for the super-obese by over seven times. This differential is likely driven by the fact that
all patients with a BMI above 40 are not the same. A BMI over 45 or 50 is at a much
higher risk for revision than a BMI just over 40 (Chapter 2).
Bariatric surgery and other nonoperative weight loss measures have been proposed to
assist morbidly and super-obese patients to attain a lower BMI and hopefully lead to a
lower risk profile and cost. Additionally, a potential benefit of weight loss is that hip
arthritis symptoms may improve sufficiently that an arthroplasty may not be needed at
that time. Research to date has provided conflicting evidence on the impact of bariatric
surgery prior to arthroplasty with some reports suggesting no improvement,18–20 other
studies suggesting lower complication rates,13,21 and others reporting higher complication
rates for the arthroplasty.22,23 Nonoperative weight loss treatments have not been very
successful for weight loss for patients with a BMI over 40. Huffaker and Giori24
conducted a retrospective study of a structured nonoperative weight loss program, and
found that only 17% of patients with a BMI over 40 lost enough weight to bring their
BMI below 40. Of the patients with a BMI over 45, less than 10% of patients reached that
same goal. In addition, nonoperative weight loss options have not been shown to improve
the complication profile for arthroplasty. There are also concerns that weight loss puts
patients in a catabolic state leading to poorer healing and higher risk of infections and
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wound complications.25 As of yet, there are no clear pathways to improve the
perioperative risk profile of morbidly and super-obese patients.
Morbidly and super-obese are at highest risk for losing access to arthroplasty despite their
comparable improvements in functional outcomes. In both the US and Canadian
healthcare systems, the economic incentives are to provide arthroplasty care for those
who would be the cheapest to care for since there is no risk adjusted reimbursement. As
well, worldwide, many hospitals are scored based on their reoperation and readmission
profile, and their annual arthroplasty volumes and budget may be affected by their
reported outcomes. By operating on more morbidly or super-obese patients their outcome
metrics may suffer and consequently could be penalized with lower funding for
arthroplasty. Concurrently, in the US, surgeons are starting to be rated based on the
complication profile including one published by Propublica26 that does not account for
patient risks. US News and World Report is planning to publish an arthroplasty surgeon
rating based on outcomes in the Fall of 2017. It remains to be seen whether it will
account for the risk profile of patients.27 Due to a multitude of reasons, both surgeons and
hospitals are being incentivized to focus only on the short term risks regardless of the
potential longer term benefits. This jeopardizes arthroplasty access for morbidly and
super-obese patients when they have no clear pathway to either improve their symptoms
or improve their risk profile.
One of the limitations of our study is that it is a retrospective chart review for most of the
reported outcomes. We did have prospectively collected data for functional outcome
scores, but other results were obtained from a review of the electronic medical records.
As the regional tertiary arthroplasty center, we tend to capture most
complications/revisions, but we could have underestimated events that did not get
referred back to our institution. Another limitation of our study relates to the low
frequency of events such as revision and VTEs, where we may have had too few patients
to be powered to detect a true difference. Consequently, we were only able to detect a
difference for the super-obese group. In addition, owing to the small sample sizes for
each cohort, the results may be affected by outliers. Furthermore, as a study from a single
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tertiary care institution in Canada, our results may not be generalizable to community
institutions or those outside of Canada.
A strength of this study is that our institution is a regional tertiary referral center for
arthroplasty. Nearly all readmissions, ER visits, and subsequent revisions are transferred
to or taken care of at our hospital. We also have access to an electronic records sharing
system, which allows us to capture any visits or readmissions to all the hospitals within
our region (most hospitals within a 100 kilometer radius of our institution).
In conclusion, the morbidly-obese and super-obese total hip arthroplasty patients incur
greater costs during the first 90-days than the non-obese cohort. All BMI cohorts have
clinically significant improvements in function that are comparable to the non-obese
cohort. Owing to the combined pressures on hospitals and surgeons in North American
and many healthcare systems in the developed world, there will be a high risk that the
morbidly-obese and super-obese will lose access to arthroplasty care due to their higher
90-day risks and costs. Health care policies do not account for the longer-term potential
benefits of arthroplasty. Preoperative health optimization of obesity is an important topic
of future research, but as of now we do not have an obvious method to achieve it. In the
interim, thorough preoperative counseling of morbidly-obese and super-obese patients is
warranted, but arbitrary restrictions should not be used to deny arthroplasty access since
these patients have no effective alternatives and demonstrate equivalent progress to
patients in lower BMI levels and have clinically significant functional improvements.
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Chapter 4

4

Cost-Effectiveness of Total Hip Arthroplasty versus
Nonoperative Management in Non-obese, Overweight,
Obese, Severely-Obese, Morbidly-Obese, and SuperObese Patients

4.1 Introduction
Currently, there are about 250,000 total hip arthroplasties (THAs) performed each year in
the United States. Those numbers are projected to increase to 572,000 by 2030.1 The
demand is increasing rapidly due to a combination of an aging population and an
increasing level of obesity in the country.2,3 Not all obese individuals (BMI>30) have the
same risk profiles with surgery. Higher BMI (i.e. BMI>40 and BMI>50) have a greater
risk for perioperative complications, infections, and revision,4–6 which leads to higher
costs of care.7 Both the United States and Canada have healthcare policies that pay a
fixed amount for taking care of an arthroplasty patient, which typically does not account
for the increased risks and costs of patients with comorbidities. In addition to the
financial risks, both providers and hospitals are commonly evaluated on quality metrics
that frequently do not account for the risk profile of their patients. In the metrics that do
account for risk profile, they likely do not adequately adjust for the risk.8,9 Physicians and
hospitals may be penalized by caring for higher risk patients such as extremely obese
individuals. As a result many providers have arbitrarily chosen specific BMI levels
(ranging from 35-45) at which they will not offer arthroplasty. These thresholds do not
account for the long-term benefits of arthroplasty over the expected lifetime of the
implant. Patients at all obesity levels have been shown to have significant improvements
in pain, function, and activity levels after an arthroplasty.10–12 The alternative
nonoperative options for hip arthritis can mitigate symptoms, but do not correct the
underlying pathology which can further progress.13 The question arises whether THA is
cost-effective relative to nonoperative management over a longer time horizon after
accounting for the risks and benefits related to BMI.
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The purpose of our study is to estimate the cost-effectiveness of performing a THA
versus nonoperative management (NM) for non-obese (BMI 18.5-24.9), overweight (2529.9), obese (30-34.9), severely-obese (35-39.9), morbidly-obese (40-49.9), and superobese (50+) cohorts. We hypothesize that although the higher BMI cohorts will
experience greater costs, the additional expense would be justified by significant
improvements in quality of life compared to nonoperative care.

4.2 Methods

Figure 4-1: Markov decision model
We constructed a Markov model (Figure 4-1) with Excel 2007 to compare the costs and
quality-adjusted life years (QALYs) of NM and THA for six BMI cohorts (non-obese
(BMI 18.5-24.9), overweight (25-29.9), obese (30-34.9), severely-obese (35-39.9),

59

morbidly-obese (40-49.9), and super-obese (50+)). Patients entering the model were
assumed to have maximized nonoperative management and would be candidates for a
THA. Consequently, those that entered the NM treatment arm would continue at the same
functional level until the natural history of hip arthritis progressed to a worse state or they
died. The THA treatment arm assumed the patient either does well following surgery, or
has a complication requiring a revision. The patient can have up to two revisions prior to
transitioning to a chronically failed arthroplasty state. Transition probabilities, healthrelated quality of life weights, and costs for each health state in each BMI cohort were
obtained from the literature (Table 4-1 to 4-4). Given the differences in prices in the US
and Canada, we conducted separate analyses for the US and Canadian cost data. An
annual discount rate of 3% was applied to all costs and utilities.

4.2.1

Transition Probabilities

The base-case annualized probabilities for conversion of a primary to revision 1 state and
revision 1 state to revision 2 state were calculated from the 2016 Australian Registry,
which reported an 8% risk for revision at 15 years for primary THA and 20% risk at 10
years for the first revision.14 There were no published estimates for the probability of a
chronically failed revision, and we assumed a 1.5% greater absolute annualized risk than
revision 1 to revision 2. The relative risks were scaled up for the higher BMI cohorts
based on the results of our meta-analysis (Chapter 2) and Wagner et. al.15 The 2007
Australian Registry reported a hazard ratio of 1.383 for increased risk of mortality with a
revision18 which we used to calculate the mortality for revision 2 and a failed
arthroplasty. The same mortality rates were used across all BMI cohorts. The literature
suggests that obese patients undergo arthroplasty at a younger age than a non-obese
individual, but generally have more comorbidities that balances out their lower mortality
risk from younger age.19–21 Prior studies of nonoperative arthritis management reported a
risk for arthritis progression of 3.33%16-6%.17 Arthritis in higher BMI categories likely
progresses faster than the lower BMI categories. Since literature comparing the rate of
progression across BMI levels was not identified, we used the conservative 3.33%
parameter for our model for all BMI cohorts, which would favor the NM treatment.
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Table 4-1: Transition Probabilities for Surgical and Nonoperative Model
Health
State
Primary to
Revision 1

Base Case Probability
Non- Overweight Obese Severely- Morbidly- SuperObese
Obese
Obese
Obese
0.51%
0.51%
0.51%
0.72%
1.03%
2.00%

Revision 1 1.84%
to Revision
2

1.84%

1.84%

2.58%

3.70%

5.06%

Revision 2 3.34%
to Failure
Progression
of Hip
Arthritis
Mortality
of Primary
THA
Mortality
of Revision
1
Mortality
of Revision
2
Mortality
of Failed

3.34%

3.34%

4.68%

6.71%

9.18%

4.2.2

3.33%

Reference
2016
Australian
Registry,14
Wagner et.
al.,15 metaanalysis,
assumption
2016
Australian
Registry,14
Wagner et.
al.,15 metaanalysis,
assumption
Assumption

4.60%

Chang et.
al.16, Mota et.
al.17
2016
Australian
Registry14
2007
Australian
Registry18
Assumption

6.36%

Assumption

2.35%
3.33%

Utilities

McLawhorn et. al. reported the preoperative and postoperative utility scores for hip
arthritis across a range of BMI classes that corresponded to our BMI cohorts.10 They did
not have a super-obese group, nor did any from our systematic review that measured
utility scores. We therefore extrapolated the trend found in McLawhorn et. al.'s study10
for this cohort based on the trend across their BMI cohorts. Utility scores after a revision
were obtained from Postler et. al.22, which we used as the non-obese utility score. For the
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other BMI cohorts' post revision utility score, we assumed a similar decrease in utility as
was reported for the primary utility scores in McLawhorn et. al.10 We assumed revision 2
resulted in 90% the utility of revision 1.23 We assumed that arthritis that has progressed
would have the same percentage decrease from preoperative utility as reported in the
literature for all patients in general (not specified by BMI).16,17 Larger BMI cohorts likely
would have a greater worsening in utility scores than the non-obese cohorts, but due to a
lack of literature on the topic we used the conservative assumption that they had the same
degree of worsening.
Table 4-2: Utility Values for Surgical and Nonoperative Model
Health State

Base Case Utility
Reference
Non- Overweight Obese Severely- Morbidly- SuperObese
Obese
Obese
Obese
Preoperative 0.66
0.66
0.62
0.58
0.54
0.5
McLawhorn
et. al.10
Arthritis
0.36
0.36
0.33
0.31
0.29
0.27
Mota et. al.,17
Progression
Chang et.
al.16
Primary
0.9
0.89
0.87
0.84
0.85
0.83
McLawhorn
THA
et. al.10
Revision 1
0.8
0.79
0.77
0.74
0.75
0.73
Postler et.
al.,22
Assumption
Revision 2
0.72
0.71
0.69
0.67
0.68
0.66
McLawhorn
et. al.,23
Assumption
Failed
0.5
0.49
0.47
0.44
0.45
0.43
Postler et.
al.,22
Assumption

4.2.3

Costs

US Costs for primary THA and revision 1 were obtained from Kremers et. al. 90-day cost
of care for different BMI levels, which are in 2010 US dollars.7 The Canadian costs for a
primary THA were based on our retrospective costing study looking at 90-day costs at
our institution, which was calculated in 2017 Canadian dollars (Chapter 3). Since we did
not have costing data for super-obese (BMI>50) patients and revisions by BMI category,
we assumed a similar scaling in costs relative to the other groups reported in Kremers et.
al.7 For revision 2 in both the US and Canadian costs, we assumed that it cost 10% more
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than revision 123 Based on US literature, we estimated annual cost of follow up for
arthroplasty care of $581 in 2012 US dollars, as reported in Bedair et. al.25 This was
converted to 2017 Canadian dollars by using purchasing power parities and adjusting for
inflation. It has been reported that the costs of nonoperative arthritis care in the quarter
prior to an arthroplasty can be US$2,094-3,100,24 while another study reported a median
annual cost of $1,630 in 2002 Canadian dollars.26 For the US base-case annual NM cost,
we used the value of $1,733 (converting the median annual cost in Canadian dollars to
US dollars with purchasing power parities and then accounting for inflation for 2017 US
dollars), and tested a wider distribution in sensitivity analyses. Gupta et. al.26 reported the
annual direct medical costs hip arthritis in Canadian dollars, which was used for the
Canadian costs after adjusting for inflation. Only the direct costs of medical care for an
arthritic hip were accounted for in the model. All costs were inflation adjusted for 2017
values. Indirect costs were not included.
Table 4-3: US Costs for Surgical and Nonoperative Model
Health State
Primary
THA
Revision 1
Revision 2
Annual
Nonoperative
Care
Annual
follow up of
primary and
revision
arthroplasties

Base Case Cost
NonOverweight Obese Severely- MorbidlyObese
Obese
Obese
$22,672
$21,509
$21,220 $22,590
$24,069
±1,386
±5,202
±3,169
±1,589
±5,438
$30,750
$30,070
$30,579 $32,253
$30,710
±1,880
±7,273
±4,566
±2,269
±6,947
$33,825
$33,077
$33,638 $35,479
$33,781
±2,068
±8,000
±5,023
±2,496
±7,643
$2,128±1,000

$622 ±400

Reference
SuperObese
$25,190
±5,699
$40,748
±9,218
$44,823
±10,140

Kremers et.
al.7
Kremers et.
al.7
McLawhorn
et. al.23
Chang et.
al.,16 Berger
et. al.,24
Gupta et.
al.26
Chang et.
al.16, Bedair
et. al.25
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Table 4-4: Canadian Costs for Surgical and Nonoperative Model
Health State

Base Case Cost
Reference
NonOverweight Obese Severely- Morbidly- SuperObese
Obese
Obese
Obese
Primary
$10,315
$11,392
$11,150 $10,449
$13,134
$13,765 Chapter 3
THA
±1,848
±6,936
±4,225 ±2,119
±7,250
±7,598
Revision 1
$13,990
$15,926
$16,068 $14,919
$16,781
$22,267 Chapter 3,
±2,506
±9.697
±6,088 ±3,025
±9,263 ±12,291 Kremers et.
al.7
Revision 2
$15,389
$17,519
$17,674 $16,411
$18,460
$24,493 McLawhorn
23
±2,757 ±10,666 ±6,697 ±3,328 ±10,190 ±13,520 et. al.
Annual
Chang et.
$1,733±1,000
Nonoperative
al.,16 Berger
Care
et. al.,24
Gupta et.
al.26

Annual
follow up of
primary and
revision
arthroplasties

4.2.4

$798 ±400

Chang et.
al.16, Bedair
et. al.25

Analysis

The model was simulated for a 15 year time period with each cycle lasting one year. A 15
year time period was chosen in order to have the longest time period for which reliable
parameter data was available. We calculated the incremental cost-effectiveness ratio
(ICER) for THA versus NM for each of the six BMI cohorts in both a US and Canadian
system. To determine model robustness with the base-case parameters, one-way threshold
sensitivity analyses were performed to determine the point at which the ICER exceeded
the willingness to pay threshold of $25,000/QALY (USD) for the US analysis and
$10,000/QALY (CAD) for the Canadian analysis. These values were chosen since the
current average payment for the US Medicare bundled payment system is $25,565 (USD)
and approximately $10,000 (CAD) in Canada.27 In addition, a Monte Carlo probabilistic
sensitivity analysis was performed with the upper and lower bounds reported in Tables 41 to 4-4. We ran 10,000 iterations for the sensitivity analysis. For the costs a gamma
distribution was used and for transition probabilities and utilities a beta distribution was
used. Distribution parameters were calculated using the method of moments.23,28
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4.3 Results
4.3.1

US Cost Analysis

Table 4-5: US Base Case Results
Nonoperative Nonoperative Incremental Incremental
BMI Group Cost
QALY
Cost
QALY
ICER
Non-Obese $21,390
6.00 $18,096
2.99 $6,043
Overweight $21,390
6.00 $16,699
2.89 $5,770
Obese $21,390
5.64 $16,585
3.06 $5,425
SeverelyObese $21,390
5.27 $22,866
3.10 $7,382
MorbidlyObese $21,390
4.91 $29,408
3.53 $8,338
Super-Obese $21,390
4.55 $59,705
3.59 $16,651
With the US base case all BMI cohorts had ICERs less than $17,000/QALY (Table 4-5).
The super-obese had the highest ICER of $16,651/QALY, while the obese had the lowest
ICER of $5,425/QALY. All the other BMI cohorts had ICERs from $5,700 to $8,400 for

Incremental Cost ($)

the base-case.
$60,000
$50,000
$40,000
$30,000
$20,000
$10,000
$0.00

1.00

2.00
3.00
Incremental QALYs

Non-Obese

Overweight

Obese

Severely-Obese

Morbidly-Obese

Super-Obese

25K WTP

50K WTP

100K WTP

4.00

Figure 4-2: US Incremental Costs vs Incremental QALYs for THA over
Nonoperative Management for Different BMI Cohorts
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Table 4-6: US One-Way Sensitivity Threshold Analysis for ICER>$25,000, base case
values are in parenthesis
Parameter
Transition
Probabilitie
s
Primary to
Revision 1
Revision 1
to Revision
2
Revision 2
to Failed
Arthroplast
y
Primary
Mortality
Revision 1
Mortality
Revision 2
Mortality
Failed
Arthroplast
y Mortality
Arthritis
Progression
Utilities
Primary
Arthroplast
y
Revision 1
Revision 2
Failed
Arthroplast
y
Preoperativ
e Arthritis
Costs
Primary
Revision 1

NonObese

BMI Category
Overweigh Obese
Severelyt
Obese

Morbidly Super-Obese
Obese

>3.33%
(0.51%)
-

>3.33%
(0.51%)
-

>3.52%
(0.51%)
-

>3.36%
(0.72%)
-

>4.16%
(1.03%)
-

>3.26%
(2.00%)
-

-

-

-

-

-

-

>22.19%
(2.35%)
-

>22.62%
(2.35%)
-

>23.90%
(2.35%)
-

>21.53%
(2.35%)
-

>21.92%
(2.35%)
-

>12.45%
(2.35%)
-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

<0.67
(0.90)

<0.66
(0.89)

<0.62
(0.87)

<0.61
(0.84)

<0.60
(0.85)

<0.69
(0.83)

-

-

-

-

-

-

>0.91
(0.66)

>0.90
(0.66)

>0.88
(0.62)

>0.82
(0.58)

>0.80
(0.54)

>0.63
(0.50)

>$79,436
($22,672)

>$77,161
($21,509)

>$81,060
($21,220)

>$77,165
($22,590)

>$208,725
($30,750)

>$204,558
($30,070)

>$218,198
($30,579)

>$158,437
($32,253)

>$82,832
($24,069
)
>$131,55
1

>$55,125
($25,190
)
>$69,949
($40,748
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Revision 2

>$2,546,7
07
($33,825)

>$2,496,7
28
($33,077)

>$2,682,6
93
($33,638)

>$1,344,3
63
($35,479)

Annual
Arthroplast
y Followup
Annual
Nonoperati
ve Care

>$6,278
($622)

>$6,168
($622)

>$6,58
($622)

>$6,064
($622)

($30,710
)
>$796,43
8
($33,781
)
>$6,488
($622)

-

-

-

-

-

)

-

>$214,14
4
($44,823
)
>$3,620
($622)

Our model was sensitive to the following parameters (the threshold was exceeded with a
transition or utility number between 0 and 1, or any non-negative cost value): transition
from primary to revision 1, mortality of primary THA, utility scores for primary THA,
utility scores for preoperative arthritis, and costs of primary, revision 1, revision 2, and
annual arthroplasty follow-up (Table 4-6). The sensitivity analysis demonstrated that the
model was stable to a wide-range of parameters. The most critical parameter in the model
is the probability of transition from primary to revision 1. The one-way sensitivity
analysis threshold for the super-obese was 3.26% which is close to the 2% base case
predicted for the super-obese group's annualized revision rate. This means that the results
for the super-obese are extremely dependent on their risk of revision. Another important
parameter is the preoperative utility score of a super-obese patient. If their preoperative
utility is greater than 0.63, then a THA would not be cost-effective at a $25,000/QALY
threshold. In order to significantly change our conclusions, the other parameters
identified by the sensitivity analysis would require values dramatically different from the
base case that would not be realistic. For example, the mortality rate would need to be ten
times that reported in the literature.
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Figure 4-3: Plot of US Monte Carlo Simulation of Incremental Costs and QALYs
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Figure 4-4: Percentage of Cases that Are Cost-Effective by Willingness-to-Pay
Threshold in US Monte Carlo Simulation
Our probabilistic sensitivity analysis demonstrated that, in the vast majority of
simulations, performing a THA would be cost-effective at a willingness-to-pay threshold
of $30,000/QALY (Figure 4-3 & 4-4). We used a broad range of parameter values (based
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on the gamma and beta distributions as noted in the methods) for our simulations to
demonstrate the robustness of the results of our model, and they show with a willingnessto-pay threshold of $30,000/QALY, THA is cost-effective across all BMI groups. At that
threshold, the model found THA cost-effective in comparison to NM for 100% of the
non-obese, overweight, annd severely-obese simulations, 99.99% of obese simulations,
99.96% of morbidly-obese simulations, and 96.65% of super-obese simulations.

4.3.2

Canadian Cost Analysis

Table 4-7: Canadian Base Case Results
Nonoperative Nonoperative Incremental Incremental
BMI Group Cost
QALY
Cost
QALY
ICER
Non-Obese $17,420
6.00 $5,713
2.99 $1,908
Overweight $17,420
6.00 $7,456
2.89 $2,576
Obese $17,420
5.64 $7,263
3.06 $2,376
SeverelyObese $17,420
5.27 $8,169
3.10 $2,637
MorbidlyObese $17,420
4.91 $14,909
3.53 $4,227
Super-Obese $17,420
4.55 $31,468
3.59 $8,776
The base-case Canadian model found that all BMI cohorts had an ICER below
$10,000/QALY (Table 4-7). The super-obese cohort had the largest ICER for THA over
NM of $8,776/QALY, while the other cohorts had an ICER ranging from $1,9004,300/QALY.

Incremental Cost ($)
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Figure 4-5: Canadian Incremental Costs vs Incremental QALYs for THA over
Nonoperative Management for Different BMI Cohorts
Table 4-8:Canadian One-Way Sensitivity Threshold Analysis for ICER>$10,000
Parameter
Transition
Probabilities
Primary to
Revision 1
Revision 1 to
Revision 2
Revision 2 to
Failed
Arthroplasty
Primary
Mortality
Revision 1
Mortality
Revision 2
Mortality
Failed
Arthroplasty
Mortality
Arthritis
Progression
Utilities

Non-Obese

Overweight

BMI Category
Obese
SeverelyObese

>3.18%
(0.51%)
-

>2.56%
(0.51%)
-

>2.73%
(0.51%)
-

>3.12%
(0.72%)
-

>2.98%
(1.03%)
-

>2.33%
(2.00%)
-

-

-

-

-

-

-

>21.13%
(2.35%)
-

>18.20%
(2.35%)
-

>19.46%
(2.35%)
-

>19.89%
(2.35%)
-

>15.74%
(2.35%)
-

>5.20%
(2.35%)
-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

MorbidlyObese

SuperObese
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Primary
Arthroplasty
Revision 1
Revision 2
Failed
Arthroplasty
Preoperative
Arthritis
Costs
Primary
Revision 1
Revision 2

<0.65
(0.90)
-

<0.67
(0.89)
-

<0.63
(0.87)
-

<0.60
(0.84)
-

<0.63
(0.85)
-

<0.78
(0.83)
-

>0.93
(0.66)

>0.90
(0.66)

>0.88
(0.62)

>0.83
(0.58)

>0.76
(0.54)

>0.55
(0.50)

>$34,546
($10,315)
>$89,961
($13,990)
>$1,088,049
($15,389)
>$3,212
($798)

>$32,877
($11,392)
>$83,287
($15,926)
>$968,611
($17,519)
>$2,939
($798)

>$34,457
($11,150)
>$89,144
($16,068)
>$1,049,462
($17,674)
>$3,120
($798)

>$33,257
($10,449)
>$67,654
($14,919)
>$563,417
($16,411)
>$3,072
($798)

>$33,493
($13,134)
>$51,719
($16,781)
>$282,695
($18,460)
>$2,830
($798)

>$18,153
($13,765)
>$26,547
($22,267)
>$49,313
($24,493)
>$1,238
($798)

-

-

-

-

<$1,296
($1,733)

Annual
Arthroplasty
Follow-up
Annual
Nonoperative
Care

Our one-way sensitivity analysis for the Canadian costs identified the following
parameters as critical to the model: transition from primary to revision 1, mortality of
primary THA, utility scores for primary THA, utility scores for preoperative arthritis, and
costs of primary, revision 1, revision 2, and annual arthroplasty follow-up (Table 4-8).
Given the lower ICER threshold used for this analysis, the results of the super-obese
group analysis was most sensitive to the primary to revision 1 transition, preoperative and
primary arthroplasty utility, and costs for primary, revision 1, annual arthroplasty followup and annual nonoperative care. Our base case for the primary to revision 1 transition
was 2%, and the sensitivity analysis identified 2.33% as the transition for an ICER of
$10,000/QALY. Also, if a super-obese patient has a preoperative utility greater than 0.55
(base estimate 0.5), then it would be more cost-effective to do NM. The base case utility
of a primary arthroplasty was 0.78, and the sensitivity analysis identified 0.83 as the
threshold. The cost parameters identified earlier are also close to the base case. The other
BMI group's parameters identified by the sensitivity analysis would require values
dramatically different from the base case and would be extremely unlikely to reach those
levels.

71

110000

Incremental Cost ($)

90000
70000
50000
30000
10000
‐10000 0

0.5

1

1.5

‐30000

2

2.5

3

3.5

4

4.5

Incremental QALYs
Super‐Obese

Morbidly‐Obese

Severely‐Obese

Obese

Overweight

Non‐Obese

Linear (10K WTP)

Linear (50K WTP)

Linear (25K WTP)

Figure 4-6: Plot of Canadian Monte Carlo Simulation of Incremental Costs and
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Figure 4-7: Percentage of Cases that Are Cost-Effective by Willingness-to-Pay
Threshold in Canadian Monte Carlo Simulation
The probabilistic analysis of the ICERs with the Canadian costing data demonstrated that
in the vast majority of the simulations THA would be cost-effective compared to NM at a
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willingness-pay-threshold of $20,000/QALY (Figures 4-6 & 4-7). A wide range of
simulation parameters (based on the beta and gamma distributions) were used to
demonstrate the robustness of the model. At a willingness-to-pay threshold of
$20,000/QALY, THA was cost-effective relative to NM for 99.99% of non-obese, obese,
and severely-obese, 99.87% of overweight, 99.83% of morbidly-obese, and 95.60% of
super-obese.

4.4 Discussion
Our study results suggest that in the vast majority of cases THA would be cost-effective
for all BMI cohorts in both the US (at a willingness-to-pay threshold of $30,000/QALY)
and Canadian cost structures (at a willingness-to-pay threshold of $20,000/QALY). This
raises the issue that BMI cut-offs for THA may lead to unnecessary loss of healthcare
access.
The expanding prevalence of obesity in the United States, Canada, and other developed
countries is driving greater arthroplasty utilization rates.2 However, because of greater
risks and complication rates with higher obesity levels, some surgeons are utilizing BMI
thresholds to determine eligibility for arthroplasty.4,5 There is a greater push in this
direction due to the bundled payments for arthroplasty in both the US and Canada. These
bundled payments are not risk-stratified for patients.29 Morbidly-obese and super-obese
patients have been shown to have greater costs of care than patients of lower obesity
levels.7 In addition, surgeons and hospitals are being rated on and may be penalized due
to their complication profile in both the US and Canada.8,9 As a result, there is pressure
on clinicians to not offer arthroplasty to the morbidly and super-obese patients due to the
higher 90-day costs of care. Our model suggests that at a reasonable cost, THA would
lead to substantial improvements in quality of life for morbidly-obese and super-obese
patients compared to NM over a 15 year time period. Healthcare economics and other
healthcare drivers are emphasizing a focus on the short-term results and do not account
for the long-term benefits of THA. As a result, there may be a loss of access to
arthroplasty care for the morbidly and super-obese despite having the potential to benefit
substantially with surgery over the longer term.
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Bundled payment models in the US are designed such that the hospital and providers will
need to use that fixed payment to cover all the costs of care within 90 days after surgery.
As a result, hospitals that have an excessive number of readmissions and reoperations
within that time window would have increased expenses without any additional
reimbursement. This can place them at a higher risk for spending more money than they
collect. Due to this longer time window of coverage after surgery, there has been an
increased emphasis on perioperative management and medical optimization prior to
surgery. For example, more surgeons are now requiring patients to quit smoking prior to
an arthroplasty. New York University has shown improved smoking cessation results
prior to arthroplasty with a smoking counseling program that led to improved
postoperative complication rates.30 In the case of obesity, the major question is whether
and to what degree obesity can be optimized prior to surgery. Some have suggested
bariatric surgery and other weight loss measures to lower BMI level might lead to a lower
perioperative risk profile and cost. However, there is conflicting evidence on the impact
of bariatric surgery prior to arthroplasty. For complication rates, some suggest no
improvement,31–33 other studies found lower complication rates,34,35 and others report
higher complication rates.36,37 Another option is nonoperative weight loss programs.
Unfortunately, they have not demonstrated dramatic success in weight reduction for
morbidly or super-obese patients. Huffaker and Giori38 presented their work that showed
only 17% of those starting above a BMI greater than 40 would reduce their BMI below
40 in a structured weight loss program. For those patients starting at a BMI greater than
45, less than 10% achieved the same threshold. At the same time, it is unclear if the
patient achieved a BMI reduction below 40, whether that would lead to substantial
improvements in their risk profile.39 In fact, one study suggests that weight loss in the
year prior to arthroplasty had a higher risk for deep surgical site infections.33 It is thought
that the catabolic state induced by weight loss can negatively affect wound healing and
may explain those results. Future work examining the relationship between nutrition and
obesity with weight loss and bariatric surgery will be critical in improving the
preoperative risk profile for obese patients prior to an arthroplasty.40 Unfortunately to
date, there are no protocols that have clearly demonstrated the ability to shift obese
patients from a higher risk profile to a lower risk profile. However, for some patients,
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weight loss alone may be sufficient to improve the symptoms of arthritis enough that an
arthroplasty may not be needed.
A major limitation in generalizing the results of this study is the availability of utility
scores for patients prior to an arthroplasty. We utilized data published from a
retrospective study of an institutional database reporting preoperative EQ-5D utility
scores across different BMI levels.10 As a retrospective study, it is possible that patients
with a higher BMI may have had a longer wait time for surgery, and consequently, lower
preoperative EQ-5D scores than lower BMI patients. They found that the morbidly-obese
had greater improvement after THA than the non-obese. Our one-way sensitivity analysis
also identified preoperative utility as a significant parameter influencing the results of the
model. The analysis suggested that the super-obese needed a pre-operative utility score of
less than 0.63 to achieve an ICER value less than $25,000/QALY in the US model. We
could not identify a utility score in the literature for the preoperative and postoperative
utility score for the super-obese group. We used the literature on super-obese patients to
guide an assumption of the utility scores for these patients. Our study is also limited in
that we do not account for the associated comorbidities of higher BMI levels such as
metabolic syndrome and cardiac risks. Certain comorbidities such as diabetes can be
optimized preoperatively to improve outcomes after an arthroplasty. Also, this study only
evaluated the direct medical costs of hip arthritis care and did not consider the indirect
societal costs, which can be sizeable due to time off from work.
The strength of our study is that it evaluates the utility of THA versus NM for a wide
range of BMI cohorts based on the best available literature from a systematic review and
meta-analysis, and institutional chart review. A cost-effectiveness study comparing THA
versus NM for different BMI cohorts has not been performed previously, and this study
adds valuable information in better balancing the long-term risks and benefits of an
arthroplasty. Prior literature has placed too much emphasis on the short-term results, and
we hope our results draw attention to the impact over a longer time span.
In conclusion, THA is a very effective procedure to improve quality of life for patients of
all BMI levels. In the vast majority of scenarios for both US and Canadian costs, we
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found that THA was likely to be cost-effective compared to nonoperative care among all
BMI cohorts. Currently, there are no clear ways to improve the risk profile of obese
patients. As we continue to evaluate options to optimize the health of the morbidly and
super-obese, these patients should not be denied a THA, since the procedure can
dramatically improve their quality of life.
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Chapter 5

5

Conclusion

5.1 Rationale for Study
Healthcare payers in Canada, and an increasing percentage of the United States, provide
funding for arthroplasty surgeries with a simple bundled payment for an episode of care,
with no risk stratification. Concurrently, both hospitals and surgeons are increasingly
rated on their short-term arthroplasty complication rates along with other quality metrics.
If a hospital or surgeon is reported to have higher complications, there is the potential to
be penalized with lower funding levels and fewer patient visits. These factors are
incentivizing surgeons to avoid operating on patients who may be at higher risk of
perioperative complications and/or have a higher cost of care. This situation can lead to
certain populations, who may have significant long term benefit from arthroplasty, losing
access to care because they have higher short-term costs and complications.
One population that is being affected by this situation are obese patients. Patients with a
BMI higher than 40 undergoing hip and knee arthroplasty have higher costs of care and
complications compared to non-obese patients, with the risk increasing as BMI increases.
Because of this, some surgeons in Canada, the US, and Europe, have established BMI
thresholds ranging from 35-45, above which they will not offer arthroplasty as a
treatment option. Nonetheless, at mid-term follow up, patients at all BMI levels have
comparable improvements in function with arthroplasty. This begs the important question
as to whether we are unfairly discriminating against patients at higher BMI levels by
denying them surgery on the basis of their weight.
We decided to approach this study by performing a cost-effectiveness analysis to better
weigh the risks and benefits of a THA versus nonoperative care for patients of all BMI
levels over a 15-year time period. To determine the parameters for our model we
performed a systematic review and meta-analysis (Chapter 2) and an institutional chart
review (Chapter 3). We used this information to construct an economic model (Chapter
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4) and determine the incremental cost-effectiveness ratio of THA versus nonoperative
care.

5.2 Summary of Findings
In Chapter 2 and 3, we found similar results between the literature and our institutional
registry. At a BMI threshold of 40, the risk for revision surgery increases exponentially,
while the BMI levels lower than that have a comparable risk of revision. The costs also
increase dramatically at a BMI level of 40 and above. Despite this, all the BMI cohorts
demonstrated comparable improvements in their function as measured by clinical
outcome scores.
We applied the risks and benefits that were quantified in Chapter 2 and 3 to an economic
model comparing THA versus nonoperative management in Chapter 4. We applied the
BMI specific parameters from our systematic review and institution's registry and chart
review for the analysis. The results were analyzed with both US and Canadian costs over
a 15 year time period. We found that in both health care systems that performing a THA
would be cost-effective relative to nonoperative management for all BMI cohorts

5.3 Challenges
There were several challenges that were encountered during the course of the study. One
of the major limitations of the systematic review and meta-analysis was the dearth of high
quality studies on the topic. We identified only 2 prospective studies that met our
inclusion criteria, and 31 retrospective studies. The small number of internally valid
studies has the potential to limit the quality of the results. Further, several studies
combined the results for both THA and TKA. Since the impact of obesity on THA and
TKA can differ owing to the differential fat distribution between the hip and the knee, we
elected to exclude those studies that did not provide separate results for THAs. Some
studies reported results only in a graph. The corresponding authors were contacted for
detailed information from the graph. If the information, was not provided, the numbers
were approximated from the graphs in the paper. Another common way of reporting
results was using a linear regression to determine the degree of association between BMI
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and complications. However, the relationship between BMI and complications is not a
linear relationship as we demonstrated in Chapter 2 and 3. Below a BMI of 40, there
generally is not much change in the risk profiles for THA patients. However, above a
BMI of 40, the risks rise rapidly. Consequently, we elected to include those studies that
divided BMI into categories and provided the event rates for reoperations, aseptic, and
septic revisions rather than odds ratios for these complications.
In Chapter 3, we examined our institutional database to obtain the 90-day costs of care
categorized by BMI for our model. We aimed to include a cohort with a BMI greater than
50, but our database had too few patients meeting this criteria. As a result, we adjusted
our largest BMI cohort to be greater than 45, this allowed for the inclusion of 33 patients
in that cohort.
With our economic model (Chapter 4), our model may overly simplify the care and
outcomes of a patient with hip arthritis. Our nonoperative model does not account for
pharmaceutical, weight loss, physical therapy, and other options. However, most patients
would have attempted one if not more of these options prior to being considered for a
THA. As a result, our model assumed that these options were maximized prior to entering
the decision tree. The operative side of the model simplifies the possible states to
assuming that they have a well functioning arthroplasty or they undergo a revision. There
are many cases where a patient has a suboptimal improvement with the arthroplasty, but
they do not undergo a revision.

5.4 Future Studies
Our study highlights that the benefits of an arthroplasty outweigh the risks over a 15-year
time period for all BMI cohorts. However, it is clear that the risks rise significantly for
those patients with a BMI greater than 40. A prospective well-designed study could
account for any biases in selection and improve the confidence in our results.
It will be important in the future to focus on identifying techniques to improve the
perioperative risk profile of patients with a BMI greater than 40. As we noted in prior
chapters, current attempts at bariatric surgery and weight loss have not clearly
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demonstrated improvement of the risks. Nonetheless, we should continue to focus on
improving the risk profile. Perioperative optimization of morbid or super-obesity could
decrease the risk, and future cost-effectiveness analysis could help quantify the value
gained from these interventions for optimization.

5.5 Clinical Implications
The results of this study will hopefully be applied to realign the incentives in arthroplasty
care in both Canada and the US. The current system in both countries places an
inordinate emphasis on the short-term outcomes and costs of an arthroplasty. This could
lead to an unnecessary loss of arthroplasty access for patients who have a BMI greater
than 40. Our study highlights that the longer-term benefits of an arthroplasty outweigh
the short-term risks and costs. It is our hope that policy makers use this information to
adjust incentives around arthroplasty such that patients are not denied access to care.
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